WO2014147642A1 - Substituted fluoranthene-7-carbonitriles as fluorescent dyes for cell imaging applications - Google Patents
Substituted fluoranthene-7-carbonitriles as fluorescent dyes for cell imaging applications Download PDFInfo
- Publication number
- WO2014147642A1 WO2014147642A1 PCT/IN2014/000156 IN2014000156W WO2014147642A1 WO 2014147642 A1 WO2014147642 A1 WO 2014147642A1 IN 2014000156 W IN2014000156 W IN 2014000156W WO 2014147642 A1 WO2014147642 A1 WO 2014147642A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- unsubstituted
- substituted
- fluoranthene
- carbonitrile
- group
- Prior art date
Links
- 238000003384 imaging method Methods 0.000 title claims abstract description 30
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 87
- 238000000034 method Methods 0.000 claims abstract description 22
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 11
- 150000001412 amines Chemical group 0.000 claims abstract description 9
- 239000003960 organic solvent Substances 0.000 claims abstract description 7
- 150000002632 lipids Chemical class 0.000 claims description 46
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 33
- 239000011541 reaction mixture Substances 0.000 claims description 29
- 238000010186 staining Methods 0.000 claims description 27
- 150000002825 nitriles Chemical class 0.000 claims description 25
- 125000004414 alkyl thio group Chemical group 0.000 claims description 22
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 22
- 150000002148 esters Chemical class 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 claims description 19
- 239000000975 dye Substances 0.000 claims description 18
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 claims description 18
- 150000002219 fluoranthenes Chemical class 0.000 claims description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- HKDXLQTVLUWODQ-UHFFFAOYSA-N 8-[2-hydroxyethyl(methyl)amino]-10-(4-methoxyphenyl)fluoranthene-7-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=CC(N(C)CCO)=C(C#N)C2=C1C1=C3C2=CC=CC3=CC=C1 HKDXLQTVLUWODQ-UHFFFAOYSA-N 0.000 claims description 14
- 125000003277 amino group Chemical group 0.000 claims description 13
- KSBYUCMQMNSNJP-UHFFFAOYSA-N 10-(4-hydroxyphenyl)-8-piperidin-1-ylfluoranthene-7-carbonitrile Chemical compound C1=CC(O)=CC=C1C1=CC(N2CCCCC2)=C(C#N)C2=C1C1=C3C2=CC=CC3=CC=C1 KSBYUCMQMNSNJP-UHFFFAOYSA-N 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- -1 hydroxy, mercapto Chemical class 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 11
- 125000004442 acylamino group Chemical group 0.000 claims description 11
- 125000004423 acyloxy group Chemical group 0.000 claims description 11
- 125000005035 acylthio group Chemical group 0.000 claims description 11
- 125000003435 aroyl group Chemical group 0.000 claims description 11
- 125000001769 aryl amino group Chemical group 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 11
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 11
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- 125000003107 substituted aryl group Chemical group 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 230000001413 cellular effect Effects 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 9
- YDSLAMBQWDFEPY-UHFFFAOYSA-N 10-(3,4-dihydroxyphenyl)-8-piperidin-1-ylfluoranthene-7-carbonitrile Chemical compound C1=C(O)C(O)=CC=C1C1=CC(N2CCCCC2)=C(C#N)C2=C1C1=C3C2=CC=CC3=CC=C1 YDSLAMBQWDFEPY-UHFFFAOYSA-N 0.000 claims description 8
- VVTBSOCBQACROF-UHFFFAOYSA-N 8-piperidin-1-yl-10-(3,4,5-trimethoxyphenyl)fluoranthene-7-carbonitrile Chemical compound COC1=C(OC)C(OC)=CC(C=2C=3C=4C=CC=C5C=CC=C(C=45)C=3C(C#N)=C(N3CCCCC3)C=2)=C1 VVTBSOCBQACROF-UHFFFAOYSA-N 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- YAXOJTRJDUSTKZ-UHFFFAOYSA-N 10-(4-methoxyphenyl)-8-piperidin-1-ylfluoranthene-7-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=CC(N2CCCCC2)=C(C#N)C2=C1C1=C3C2=CC=CC3=CC=C1 YAXOJTRJDUSTKZ-UHFFFAOYSA-N 0.000 claims description 7
- VCLBYCPHGUBARR-UHFFFAOYSA-N 10-(4-nitrophenyl)-8-piperidin-1-ylfluoranthene-7-carbonitrile Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=CC(N2CCCCC2)=C(C#N)C2=C1C1=C3C2=CC=CC3=CC=C1 VCLBYCPHGUBARR-UHFFFAOYSA-N 0.000 claims description 6
- VHEBGDXTQDHMHV-UHFFFAOYSA-N 8-piperidin-1-yl-10-thiophen-2-ylfluoranthene-7-carbonitrile Chemical compound N#CC1=C2C(C=34)=CC=CC4=CC=CC=3C2=C(C=2SC=CC=2)C=C1N1CCCCC1 VHEBGDXTQDHMHV-UHFFFAOYSA-N 0.000 claims description 6
- CDGBJIVKSAZDGX-UHFFFAOYSA-N 8-(dimethylamino)-10-propan-2-ylfluoranthene-7-carbonitrile Chemical compound C1=CC(C=2C(C(C)C)=CC(N(C)C)=C(C#N)C=22)=C3C2=CC=CC3=C1 CDGBJIVKSAZDGX-UHFFFAOYSA-N 0.000 claims description 5
- VRHYCJOXAUCKHJ-UHFFFAOYSA-N 10-(4-aminophenyl)-8-piperidin-1-ylfluoranthene-7-carbonitrile Chemical compound C1=CC(N)=CC=C1C1=CC(N2CCCCC2)=C(C#N)C2=C1C1=C3C2=CC=CC3=CC=C1 VRHYCJOXAUCKHJ-UHFFFAOYSA-N 0.000 claims description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 4
- 238000005286 illumination Methods 0.000 claims description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 4
- FQSXSJSVKUBZDR-UHFFFAOYSA-N 8-[bis(2-hydroxyethyl)amino]-10-phenylfluoranthene-7-carbonitrile Chemical compound C=12C(C=34)=CC=CC4=CC=CC=3C2=C(C#N)C(N(CCO)CCO)=CC=1C1=CC=CC=C1 FQSXSJSVKUBZDR-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- SBMSLRMNBSMKQC-UHFFFAOYSA-N pyrrolidin-1-amine Chemical compound NN1CCCC1 SBMSLRMNBSMKQC-UHFFFAOYSA-N 0.000 claims description 2
- 238000009987 spinning Methods 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000005998 bromoethyl group Chemical group 0.000 claims 1
- 125000003914 fluoranthenyl group Chemical class C1(=CC=C2C=CC=C3C4=CC=CC=C4C1=C23)* 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 4
- 125000002560 nitrile group Chemical group 0.000 abstract description 3
- 150000000464 2H-pyran-2-ones Chemical class 0.000 abstract description 2
- 150000003997 cyclic ketones Chemical class 0.000 abstract description 2
- 125000006357 methylene carbonyl group Chemical group [H]C([H])([*:1])C([*:2])=O 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 68
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 44
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 34
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 34
- 230000005284 excitation Effects 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 210000000229 preadipocyte Anatomy 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 21
- 241000222727 Leishmania donovani Species 0.000 description 17
- 239000003480 eluent Substances 0.000 description 17
- 238000000295 emission spectrum Methods 0.000 description 17
- 238000000695 excitation spectrum Methods 0.000 description 17
- 239000007787 solid Substances 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 238000000862 absorption spectrum Methods 0.000 description 15
- 238000003756 stirring Methods 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 11
- 239000006185 dispersion Substances 0.000 description 10
- 230000009977 dual effect Effects 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- HGUQWMODRQACAI-UHFFFAOYSA-N 8-piperidin-1-yl-10-(3,4,5-trihydroxyphenyl)fluoranthene-7-carbonitrile Chemical compound OC1=C(O)C(O)=CC(C=2C=3C=4C=CC=C5C=CC=C(C=45)C=3C(C#N)=C(N3CCCCC3)C=2)=C1 HGUQWMODRQACAI-UHFFFAOYSA-N 0.000 description 6
- 241000222722 Leishmania <genus> Species 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 5
- JBXIOAKUBCTDES-UHFFFAOYSA-N 2h-acenaphthylen-1-one Chemical compound C1=CC(C(=O)C2)=C3C2=CC=CC3=C1 JBXIOAKUBCTDES-UHFFFAOYSA-N 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 239000001044 red dye Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- WDTWHAFWOQHVCF-UHFFFAOYSA-N 10-phenyl-8-pyrrolidin-1-ylfluoranthene-7-carbonitrile Chemical compound N#CC1=C2C(C=34)=CC=CC4=CC=CC=3C2=C(C=2C=CC=CC=2)C=C1N1CCCC1 WDTWHAFWOQHVCF-UHFFFAOYSA-N 0.000 description 4
- 229910015845 BBr3 Inorganic materials 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 238000012757 fluorescence staining Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- VFCWUQBKOKNPOP-UHFFFAOYSA-N 8-[2-bromoethyl(methyl)amino]-10-(4-methoxyphenyl)fluoranthene-7-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=CC(N(C)CCBr)=C(C#N)C2=C1C1=C3C2=CC=CC3=CC=C1 VFCWUQBKOKNPOP-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 0 Cc(c(*)c1*)c(-c2c(c-3c(*)c(*)c4*)c4c(*)c(*)c2*)c-3c1C#N Chemical compound Cc(c(*)c1*)c(-c2c(c-3c(*)c(*)c4*)c4c(*)c(*)c2*)c-3c1C#N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000222712 Kinetoplastida Species 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000004624 confocal microscopy Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- ILBKBRBXCXDCFB-UHFFFAOYSA-N 4-(1h-indol-2-yl)benzene-1,3-diamine Chemical compound NC1=CC(N)=CC=C1C1=CC2=CC=CC=C2N1 ILBKBRBXCXDCFB-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- DYDRWGKJAMZOLY-UHFFFAOYSA-N N,N-dimethyl-5-pentan-3-ylsulfonylnaphthalen-1-amine Chemical compound S(=O)(=O)(C1=CC=CC=2C(N(C)C)=CC=CC1=2)C(CC)CC DYDRWGKJAMZOLY-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000010859 live-cell imaging Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 2
- 229960003775 miltefosine Drugs 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- PLVCYMZAEQRYHJ-UHFFFAOYSA-N (2-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Br PLVCYMZAEQRYHJ-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- MHFRGQHAERHWKZ-HHHXNRCGSA-N (R)-edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-HHHXNRCGSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VUWXIJSTGVLREH-UHFFFAOYSA-N 1,8-bis(2-phenylethynyl)naphthalene Chemical compound C1=CC=CC=C1C#CC1=CC=CC2=CC=CC(C#CC=3C=CC=CC=3)=C12 VUWXIJSTGVLREH-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- LSXKDWGTSHCFPP-UHFFFAOYSA-N 1-bromoheptane Chemical compound CCCCCCCBr LSXKDWGTSHCFPP-UHFFFAOYSA-N 0.000 description 1
- DLKQHBOKULLWDQ-UHFFFAOYSA-N 1-bromonaphthalene Chemical compound C1=CC=C2C(Br)=CC=CC2=C1 DLKQHBOKULLWDQ-UHFFFAOYSA-N 0.000 description 1
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 1
- DWKNOLCXIFYNFV-HSZRJFAPSA-N 2-[[(2r)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-n,n,6-trimethylpyridine-4-carboxamide Chemical compound CN(C)C(=O)C1=CC(C)=NC(NC(=O)[C@@H]2N(C(=O)CC2)C2CCN(CC=3C=C(C)C(Cl)=CC=3)CC2)=C1 DWKNOLCXIFYNFV-HSZRJFAPSA-N 0.000 description 1
- CLQMKSJKBIZKEW-UHFFFAOYSA-N 2-oxo-4-piperidin-1-yl-6-(3,4,5-trimethoxyphenyl)pyran-3-carbonitrile Chemical compound COC1=C(OC)C(OC)=CC(C=2OC(=O)C(C#N)=C(N3CCCCC3)C=2)=C1 CLQMKSJKBIZKEW-UHFFFAOYSA-N 0.000 description 1
- LDEVGGJCKMHINT-UHFFFAOYSA-N 2-oxo-4-piperidin-1-yl-6-thiophen-2-ylpyran-3-carbonitrile Chemical compound N#CC=1C(=O)OC(C=2SC=CC=2)=CC=1N1CCCCC1 LDEVGGJCKMHINT-UHFFFAOYSA-N 0.000 description 1
- HOKXHJKMZVTIJZ-UHFFFAOYSA-N 2-oxo-6-phenyl-4-pyrrolidin-1-ylpyran-3-carbonitrile Chemical compound N#CC=1C(=O)OC(C=2C=CC=CC=2)=CC=1N1CCCC1 HOKXHJKMZVTIJZ-UHFFFAOYSA-N 0.000 description 1
- JFNHXLWUMCBGCZ-UHFFFAOYSA-N 4-(dimethylamino)-2-oxo-6-propan-2-ylpyran-3-carbonitrile Chemical compound CC(C)C1=CC(N(C)C)=C(C#N)C(=O)O1 JFNHXLWUMCBGCZ-UHFFFAOYSA-N 0.000 description 1
- UXHQLGLGLZKHTC-CUNXSJBXSA-N 4-[(3s,3ar)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile Chemical compound C1CC(O)CCN1C(=O)C1=CC=C(C=2[C@@H]([C@H](C3CCCC3)N(N=2)C=2C=C(Cl)C(C#N)=CC=2)CC2)C2=N1 UXHQLGLGLZKHTC-CUNXSJBXSA-N 0.000 description 1
- DBSLOXYWEAUMAJ-UHFFFAOYSA-N 4-[2-hydroxyethyl(methyl)amino]-6-(4-methoxyphenyl)-2-oxopyran-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=CC(N(C)CCO)=C(C#N)C(=O)O1 DBSLOXYWEAUMAJ-UHFFFAOYSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- FZLSDZZNPXXBBB-KDURUIRLSA-N 5-chloro-N-[3-cyclopropyl-5-[[(3R,5S)-3,5-dimethylpiperazin-1-yl]methyl]phenyl]-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine Chemical compound C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)ccc34)cc(c2)C2CC2)C[C@@H](C)N1 FZLSDZZNPXXBBB-KDURUIRLSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- NXWRCPFWNLSYMG-UHFFFAOYSA-N 6-(4-methoxyphenyl)-2-oxo-4-piperidin-1-ylpyran-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=CC(N2CCCCC2)=C(C#N)C(=O)O1 NXWRCPFWNLSYMG-UHFFFAOYSA-N 0.000 description 1
- GCVFARLHQHRIMK-UHFFFAOYSA-N 6-(4-nitrophenyl)-2-oxo-4-piperidin-1-ylpyran-3-carbonitrile Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=CC(N2CCCCC2)=C(C#N)C(=O)O1 GCVFARLHQHRIMK-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- AINKOXQRQZSMLE-UHFFFAOYSA-N COC(C(C#N)=C([S+](C)C)[S+](C)C)=O Chemical compound COC(C(C#N)=C([S+](C)C)[S+](C)C)=O AINKOXQRQZSMLE-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- YFPJFKYCVYXDJK-UHFFFAOYSA-N Diphenylphosphine oxide Chemical compound C=1C=CC=CC=1[P+](=O)C1=CC=CC=C1 YFPJFKYCVYXDJK-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 241001580017 Jana Species 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019201 POBr3 Inorganic materials 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- MCRWZBYTLVCCJJ-DKALBXGISA-N [(1s,3r)-3-[[(3s,4s)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[(1s,4s)-5-[6-(trifluoromethyl)pyrimidin-4-yl]-2,5-diazabicyclo[2.2.1]heptan-2-yl]methanone Chemical compound C([C@]1(N(C[C@]2([H])C1)C(=O)[C@@]1(C[C@@H](CC1)N[C@@H]1[C@@H](COCC1)OC)C(C)C)[H])N2C1=CC(C(F)(F)F)=NC=N1 MCRWZBYTLVCCJJ-DKALBXGISA-N 0.000 description 1
- ODEDPKNSRBCSDO-UHFFFAOYSA-N [2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C ODEDPKNSRBCSDO-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 1
- CWRYPZZKDGJXCA-UHFFFAOYSA-N acenaphthalene Natural products C1=CC(CC2)=C3C2=CC=CC3=C1 CWRYPZZKDGJXCA-UHFFFAOYSA-N 0.000 description 1
- 150000001239 acenaphthenes Chemical class 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940124578 antitrypanosomal agent Drugs 0.000 description 1
- 239000003702 antitrypanosomal agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000012094 cell viability reagent Substances 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- FQQOMPOPYZIROF-UHFFFAOYSA-N cyclopenta-2,4-dien-1-one Chemical class O=C1C=CC=C1 FQQOMPOPYZIROF-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 101150063755 dph-1 gene Proteins 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229950011461 edelfosine Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229950006905 ilmofosine Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- JCCWBLXWOYOGSL-UHFFFAOYSA-N methylsulfanyl prop-2-enoate Chemical compound CSOC(=O)C=C JCCWBLXWOYOGSL-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 1
- 238000000103 photoluminescence spectrum Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000004895 subcellular structure Anatomy 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B57/00—Other synthetic dyes of known constitution
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
Definitions
- the present invention relates to novel donor-acceptor fluoranthenes of the general formula I which can be used potentially in developing fluorescent probes, and a process of preparing said novel compounds. More particularly, the present invention relates to amine or alkoxy group as donor and nitrile group as an acceptor attached to the fluoranthene skeleton, processes for preparing the said compounds and their uses as fluorescent probes in chemical and biological sciences such as cell imaging applications, diagnostics, fluorescent tags and other useful applications.
- the present invention more particula ly relates to a compound of formula I:
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 are independently selected from the groups consisting of hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl, unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or substituted acyloxy, unsubsti
- cytoplasmic lipid droplets The formation of cytoplasmic lipid droplets is a normal cellular process and found in almost all cells under physiological or pathological conditions. Number and size of lipid droplets vary from one cell type to another. Lipid droplets have two major compartments: neutral lipids, such triacylglycerides, diacylglycerol and cholesterol esters, and a surrounding lipids, such as triacylglycerides, diacylglycerol and cholesterol esters, and a surrounding neutral lipids, such triacylglycerides, diacylglycerol and cholesterol esters, and a surrounding neutral lipids, such triacylglycerides, diacylglycerol and cholesterol esters, and a surrounding neutral lipids, such triacylglycerides, diacylglycerol and cholesterol esters, and a surrounding lipids, such as triacylglycerides, diacylglycerol and cholesterol esters, and a surrounding lipids, such as triacyl
- Lipid droplets have been considered as a "great balls of fat”. But in recent years lipid droplets regarded as complex subcellular organelles in adiposites of fat tissues (Walther et al. Annu. Rev. Biochem. 2012, 81 , 687-714). An imbalance between energy intake and expenditure accumulation of the cytoplasmic lipid droplets occurs in a variety of pathological conditions
- ergosterol In fungi and Kinetoplastid protozoans including Leishmania, ergosterol is the major storage lipid, and synthesized via type-2 fatty acid biosynthesis pathway.
- the biosynthesis pathway being unique to these organisms are thus targets by some of the major antifungal and anti- trypanosomal agents, such as ketoconazole, triclosan, miltefosine, amphotericin B.
- Lysophospholipid analogues like edelfosine, ilmofosine and miltefosine interact with various sub-cellular structures and enzymes especially those associated with cellular membranes thus interfering with metabolism of membrane lipids.
- Markers can be used to visualize and quantify lipid droplets especially to study the effect of agents that interfere with lipid metabolism in kinetoplastid parasites like Leishmania and Trypanosoma.
- Commercially available lipid markers :
- lipid markers are BODIPY, Nile Red, LipidTOX Red, LipidTOX Green, LipidTOX deep red, Monodansylpentane.
- Nile Red dye has wide spectral occupancy and cannot be used with ranges of FITC, TRITC, Texas Red.
- BODIPY 493/503 is a FITC range dye with greater affinity to Lipid droplets and smaller fluorescent spectral footprint than Nile Red.
- a new lipid marker LD540 is a near red BODIPY family dye with excellent specificity but not available commercially (Thiele C.
- Lipid TOX dyes from Invitrogen are FITC compatible but very expensive (-200 times that of BODIPY 493/503).
- l ,6-Diphenyl-l,3,5-hexatrine (DPH) is only fluorescent in hydrophobic environment used for LD visualization with fluorescence microscopy but has not been very useful since it shares its excitation and emission properties with 4',6'-diamino-2-phenylindole (DAPI) and Hoechst stains.
- novel donor-acceptor fluoranthenes have been prepared and investigated as fluorescent marker for staining neutral lipid droplets. Examples of some of these derivatives are mentioned here.
- Fluoranthene contain a rigid biphenyl structure locked into a coplanar arrangement by the presence of a fused benzene moiety.
- Few synthetic methodologies are available for the synthesis of fluoranthene derivatives, which mainly include the cycloaddition reaction of cyclopentadienone derivatives and alkynes or alkenes(Marcinow et al J. Org. Chem. 2002, 67, 3537; Viala et al J. Org. Chem. 2002, 4185; Wehmeier et al Chem. Eur. J.
- Main object of the present invention is to provide novel donor-acceptor fluoranthenes, having the general formula I.
- Another object of the invention is to provide a process for the preparation of the novel donor- acceptor fluoranthene compounds having the general formula I.
- the present invention provides a novel Donor-acceptor fluoranthenes having general formula I, and derivatives thereof
- R ⁇ R R J , R ⁇ R J , R°, R', R° are independently selected from the groups comprising hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or substituted acyloxy, unsubstituted or substituted thioa
- the unsubstituted or substituted amine group is selected from amino, pyrrolidine, piperidine, methyl amine, ethyl amine, propyl amine, dimethylamine, N-alkylalkanolamine, ⁇ , ⁇ -dialkanolamine and pegylatedamine.
- the representative compounds include;
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 are independently selected from the groups comprising hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl, unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstit
- X is a donor group comprising unsubstituted or substituted amine, unsubstituted or substituted alkoxyl, unsubstituted or-substituted alkylthio group;
- the organic solvent is selected from the group comprising DMF, THF, DMSO, DCM and isopropanol.
- the base is selected from the group comprising KOH, NaOH, NaH, KH, K 2 C0 3 and Cs 2 C0 3
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 are independently selected from the groups comprising hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or substituted acyloxy, unsubstitute
- 3 ⁇ 4aid fluorescence-based cell imaging or analysis is either a monocolor or a multi-color imaging or analysis.
- a method for fluorescence-based imaging or analysis of cells and/or cellular components comprising the following steps: i) staining cellular components with a donor-acceptor fluoranthenes having the general formula I, and derivatives thereof wherein Rl , R2, R3, R4, R5, R6, R7, R8 are independently selected from the groups comprising of hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstituted or substituted arylamino, unsubstit
- step (iii) detecting the light emitted in step (ii);
- step iv) optionally, generating images with the emission data obtained in step iii);
- the cellular components stained with the fluoranthene dye of formula I in step i) are lipid droplets.
- 1 , 2 or 3 other excitable fluorescent dye(s) are used, resulting in 2-color, 3-color or 4-color imaging.
- living or fixed cells are subjected to said fluorescence-based imaging or analysis of cells and/or cellular components.
- a confocal 'laser scanning microscope In still another embodiment of the present invention, a confocal 'laser scanning microscope, a spinning disc microscope, a two-photon microscope, a conventional epifluorescence microscope, a structured illumination microscope, or a single plane illumination microscope is used.
- Even furthermore embodiment of the present invention relates to the compounds are prepared by reacting 2H-pyran-2-ones in isolated or rigid conformations with cyclic ketones containing methylene carbonyl moiety in the presence of a base in an organic solvent.
- Table 1 represents the photophysical properties of the compounds of the invention.
- Table 2 represents the solvatochromic properties of compound 8.
- Figure 1 illustrates the reaction sequence resulting in the preparation of various fluoranthene derivatives.
- Figure 2 illustrates absorption, excitation and emission spectra of compound 1 in Water.
- Figure 3 illustrates absorption, excitation and emission spectra of compound 2 in Water.
- Figure 4 illustrates absorption, excitation and emission spectra of compound 3 in Water.
- Figure 5 illustrates absorption, excitation and emission spectra of compound 4 in Water.
- Figure 6 illustrates absorption, excitation and emission spectra of compound 5 in Water.
- Figure 7 illustrates absorption, excitation and emission spectra of compound 6 in Water.
- Figure 8 illustrates absorption, excitation and emission spectra of compound 8 in Water.
- Figure 9 illustrates absorption, excitation and emission spectra of compound 9 in Water.
- Figure 10 illustrates absorption, excitation and emission spectra of compound 10 in Water.
- Figure 11 illustrates absorption, excitation and emission spectra of compound 11 in Water.
- Figure 12 illustrates absorption, excitation and emission spectra of compound 12 in Water.
- Figure 13 illustrates absorption, excitation and emission spectra of compound 13 in Water.
- Figure 14 illustrates absorption, excitation and emission spectra of compound 14 in Water.
- Figure 15 illustrates absorption, excitation and emission spectra of compound 15 in Water.
- Figure 16 Solvatochromism spectra of compound 8 in solvent of varying polarity.
- Figure 17 illustrates excitation spectra of compound 8 with BODIPY and Nile Red dyes in water
- Figure 18 illustrates emission spectra of compound 8 with BODIPY and Nile Red dyes in water.
- Figure 19 illustrates L. donovani promastigotes stained with 300nM Nile Red in PBS for 10 min. in room temperature.
- Figure 20 illustrates L. donovani promastigotes stained with lOOnM compound 8 in PBS for 2h in room temperature.
- FIG 21 illustrates dual staining of L. donovani promastigotes with Nile Red and compound
- Figure 22 illustrates 3T3-L1 pre-adipocytes stained with 300nM Nile Red for 10 min at 37°C / 5% C0 2 in medium (DMEM).
- Figure 23 illustrates 3T3-L1 pre-adipocytes were stained with lOOnm of compound 8 for 20 min. at 37°C / 5% C0 2 in medium (DMEM) on confocal dishes and directly analyzed by confocal microscopy.
- DMEM medium
- Figure 24 illustrates dual staining of 3T3-L1 pre-adipocytes with Nile Red and compound 8.
- Figure 25 illustrates dual staining of 3T3-L1 pre-adipocytes with Hoeschst and compound 8.
- Figure 26 shows cell viability assessment of compound 8 in 3T3-L1 pre-adipocytes.
- Figure 27 shows cell viability assessment of compound 8 in L. donovani promastigotes.
- the present invention relates to novel donor-acceptor fluoranthenes of the general formula I which can be used potentially in developing fluorescent probes, and a process of preparing said novel compounds. More particularly, the present invention relates to amine or alkoxy group as donor and nitrile group as an acceptor attached to the fluoranthene skeleton, processes for preparing the said compounds and their uses as fluorescent probes in chemical and biological sciences such as cell imaging applications, diagnostics, fluorescent tags and other useful applications.
- fluorescent probe' refers to a fluorophore, which may be used to localize within a specific region of a biological specimen or to respond to a specific analyte/substance.
- 'fluorescent tag' refers to a fluorescent molecule that is attached chemically to aid in the labeling and detection of a biomolecule such as a protein, antibody, or amino acid.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 are independently selected from the groups consisting of hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or substituted acyloxy,
- X is a donor group consisting of unsubstituted or substituted amino, unsubstituted or substituted alkoxyl, unsubstituted or substituted alkylthio group
- substituted means substitution with one or more halogen(s), nitrile(s), ester(s), hydroxy(s), alkoxy(s), mercapto(s), carbontrifluoride(s), nitro(s), amino group(s) or
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 are independently selected from the groups consisting of hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl, unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted ;or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or substituted acyloxy,
- X is a donor group consisting of unsubstituted or substituted amino, unsubstituted or substituted alkoxyl, unsubstituted or substituted alkylthio group
- reaction may proceeds in a common organic solvent particularly DMF, THF, DMSO, DCM, isopropanol in the presence of a base particularly KOH, NaOH, NaH, KH, K 2 C0 3 , Cs 2 C0 3 at a temperature ranging between -78°C to 100°C for a period ranging between 1 minute to 24 hr.
- the present invention is to provide the compounds having the general formula I which are useful in preparing fluorescent probes for cell imaging applications and other useful biological applications such as developing diagnostic kits.
- Example 8-10 Compound 10-(4- methoxyphenyl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile (Example 3) or 10- (benzo[d][l,3]dioxol-5-yl)-8-(piperidin-l -yl)fluoranthene-7-carbonitrile (Example 5) or 8- (piperidin-l-yl)-10-(3,4,5-trimethoxyphenyl)fluoranthene-7-carbonitrile (Example 6) (1 mmol, lequiv.) was dissolved in dry CH2CI2 (10 ml) and BBr 3 (2 equiv.
- Solvatochromism Due to the difference in the dipole moments of the donor-acceptor molecules in the ground and excited states and their stabilization by polar or non-polar solvent molecules through various noncovalent interactions like hydrogen bonding, solvation or dipole-dipole interactions, novel donor-acceptor fluoranthenes exhibit solvatochromic behaviour as shown in Figure 16.
- the absorption and PL spectra of compound 8 were examined using solvents of varying polarity as depicted in Table 2.
- Excitation and emission spectra of compound 8 were examined with commercially available lipid droplet probes (Nile Red and BODIPY) in 0.2 % DMSO in water as shown in drawing accompanying the specification ( Figure 17 and Figure 18). An excitation maximum of compound 8 was observed at 332 nm and 435 nm. Excitation maxima of BODIPY and Nile Red were observed at 493 and 597 nm respectively while emission maxima of these fluorescent probes were 550, 503 and 657 nm respectively.
- novel fluoranthene dye showed different emission window and high stokes shift compare to the commercially available BODIPY and Nile Red dyes and therefore, it can be used in multicolor live cell imaging without background noise.
- 3T3-L1 pre-adipocyte cells were obtained earlier from American Type Culture Collection, Manassas, VA, Cat. No. CL-173 and maintained in the tissue and cell culture facility at CDRI, Lucknow. 3T3-L1 pre-adipocytes were cultured in DMEM with 10% heat-inactivated 5 FBS at 37°C. After reaching 70% confluence, cells were seeded two days before starting experiments. Leishmania donovani (strain MHOM/IN/80/Dd8) promastigotes were cultured as described previously (Nayak, R. C; Sahasrabuddhe, A. A.; Bajpai, V. K.; Gupta, C. M.; Mol. Biochem. Parasitol. 2005, 143, 152.). Briefly, cells were cultured in Dulbecco's Modified Eagles Medium (DMEM) with phenol red, L-glutamine and 4.8g/L D-glucose
- DMEM Dulbecco'
- Leishmania donovani (strain MHOM/IN/80/Dd8) cells were obtained from Dr Sahasrabudhe, Molecular and Structural Biology division of the CDRI, Lucknow. These cells were cultured in Dulbecco's Modified Eagles Medium (DMEM) with phenol ;red, L-glutamine and 4.8g/L D-glucose supplemented with 10% heat inactivated FBS and sodium pyruvate. Cells were ) checked for their health periodically and maintained in standard tissue culture flasks. After reaching an approximate density of 10 6 , they were prepared for incubation. 3T3-L1 pre- adipocytes were cultured in DMEM with 10% heat-inactivated FBS at 37°C. After reaching 70% confluence, cells were seeded and cultured for 2 days in confocal dishes before commencing experiments.
- DMEM Dulbecco's Modified Eagles Medium
- L. donovani cells briefly after harvesting, were incubated with ⁇ compound 8 for 1 hour (empirically determined) at room temperature. Afterwards, they were washed once in PBS (lx) and further incubated with either 300 nM Nile Red for 10 minutes. Cells were then
- L. donovani promastigotes stained with ⁇ compound 8 in PBS for 2h at room temperature. Lipid droplets are indicated by orange spots as indicated by arrows in Figure 20 scattered throughout the cell. Bar indicates 5 ⁇ . Imaging experiments were performed at ) Excitation wavelength at 405 nm with Emission filter of 530nm Long Pass.
- Figure 16 represents Dual staining of L. donovani promastigotes with Nile Red and compound 8.
- Cells were first incubated with compound 8 for 2h, then stained with Nile Red for 15 min at 5 room temperature. Bars indicate 5 ⁇ . Imaging experiments were performed at Excitation wavelength at 514 nm for Nile Red and 405 nm for compound 8. Staining pattern is similar with Nile Red and compound 8 as indicated by arrows in Figure 21.
- 3T3-L1 pre-adipocytes stained with 300nM Nile Red for 10 min. at 37°C/5%C0 2 in medium (DMEM). Cells were imaged with a 63x PlanApochromat Oil DIC 1.4 NA objective. Lipid droplets are distinctly stained as red dots throughout the cytoplasm as shown in Figure 22. Imaging experiments were performed at Excitation wavelength at 514 nm with Emission filter of 575nm Long Pass. Bars indicate 5 ⁇ . 5 Fluorescence staining in 3T3-L1 pre-adipocytes with compound 8:
- 3T3-L1 pre-adipocytes were stained with lOOnm of compound 8 for 20 min. at 37°C/5%C0 2 in medium (DMEM) on confocal dishes and directly analyzed by confocal microscopy. Lipid droplets are distinctly stained as orange dots throughout the cytoplasm as shown in Figure 23. Imaging experiments were performed at Excitation wavelength at 405 nm with Emission filter 3 of 505-550 nm. Bars indicate 5 ⁇ .
- Figure 24 represents Dual staining of 3T3-L1 pre-adipocytes with Nile Red and compound 8.
- Cells were first incubated with compound 8 for 2h, then stained with Nile Red for 15 min at 5 room temperature. Bars indicate 5 ⁇ . Imaging experiments were performed at Excitation wavelength at 514 nm for Nile Red and 405 nm for compound 8. Staining pattern is similar with Nile Red.
- Figure 25 represents Dual staining of 3T3-L1 pre-adipocytes with Hoechst 33342 and compound 8.
- Cells were first incubated with compound 8 for 2h, then stained with Hoechst 33342 for 10 min at room temperature. Bars indicate 5 ⁇ . Imaging experiments were performed at Excitation wavelength at 405 nm for Hoechst 33342 and compound 8.
- 3T3-L1 cells were seeded a day before experiment in confocal coverglass bottom dishes (105 cells/dish). Afterwards, cells were treated with compound 8 at concentrations of ⁇ ⁇ , 500nM, 250nM and ⁇ for 24hrs before staining with SYTOX® Green (500nM) for 15min. Samples were analyzed under the confocal microscope. Cells that had taken up the
- Figure 26 represents cell viability assessment of compound 8 in 3T3-L1 pre-adipocytes.
- L. donovani promastigotes were incubated with the compound 8 at different working concentrations (50nM, ⁇ , 5Q0nM and ⁇ ⁇ ) for the required incubation period of 3 hrs.
- dye 8 is a specific and non-toxic lipid molecular bioprobe for quantification of lipid droplets with high brightness at a low concentration of 100 nM without background noise and is better than Nile red.
- Dye 8 exhibited clearly distinct PL from the commercially available BODIPY and Nile Red dyes and it may be used as a fluorescent probe alone or in combination with other fluorophores for multi-color imaging applications.
Abstract
The present invention relates to novel donor-acceptor fluoranthenes of the general formula I which can be used potentially in developing fluorescent probes, and a process of preparing said novel compounds. More particularly, the present invention relates to amine or alkoxy group as donor and nitrile group as an acceptor attached to the fluoranthene skeleton, processes for preparing the said compounds and their uses as fluorescent probes in chemical and biological sciences such as cell imaging applications, diagnostics, fluorescent tags and other useful applications. The compounds are prepared by reacting 2H-pyran-2-ones in isolated or rigid conformations with cyclic ketones containing methylene carbonyl moiety in the presence of a base in an organic solvent.
Description
SUBSTITUTED FLUORANTHENE-7-CARBONITRILES AS FLUORESCENT DYES
FOR CELL IMAGING APPLICATIONS
FIELD OF THE INVENTION
The present invention relates to novel donor-acceptor fluoranthenes of the general formula I which can be used potentially in developing fluorescent probes, and a process of preparing said novel compounds. More particularly, the present invention relates to amine or alkoxy group as donor and nitrile group as an acceptor attached to the fluoranthene skeleton, processes for preparing the said compounds and their uses as fluorescent probes in chemical and biological sciences such as cell imaging applications, diagnostics, fluorescent tags and other useful applications.
The present invention more particula ly relates to a compound of formula I:
I
Wherein R1, R2, R3, R4, R5, R6, R7, R8 are independently selected from the groups consisting of hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl, unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or substituted acyloxy, unsubstituted or substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro;
5 Wherein X is a donor group consisting of unsubstituted or substituted amino, unsubstituted or substituted alkoxyl, unsubstituted or substituted alkylthio group. Wherein CN is a nitrile, an acceptor group.
BACKGROUND OF THE INVENTION
0
The formation of cytoplasmic lipid droplets is a normal cellular process and found in almost all cells under physiological or pathological conditions. Number and size of lipid droplets vary from one cell type to another. Lipid droplets have two major compartments: neutral lipids, such triacylglycerides, diacylglycerol and cholesterol esters, and a surrounding
5 phospholipid monolayer, which contains free cholesterol and proteins. Lipid droplets have been considered as a "great balls of fat". But in recent years lipid droplets regarded as complex subcellular organelles in adiposites of fat tissues (Walther et al. Annu. Rev. Biochem. 2012, 81 , 687-714). An imbalance between energy intake and expenditure accumulation of the cytoplasmic lipid droplets occurs in a variety of pathological conditions
D and have been recognized as metabolic syndromes, such as obesity and diabetes.
In order to study lipid accumulation in living cells fluorescence imaging plays an important role in imaging of lipid regulation. Several imaging technologies on the basis of fluorescence are available to cell biologists. Lipid droplets form functionally and morphologically diverse
5 subpopulations, no single marker protein exists that would stain the entire LDs. Therefore, the only reliable way to visualize lipid droplets in a living cell is by staining the LDs with lipophilic dyes. Small molecule organic fluorescent dyes with a variety of emission characteristics play a pivotal role in biological and material sciences. In biological perspective, these fluorescent dyes are being used as probes for imaging of specific
) intracellular organelles in living cells to understand intracellular events and elucidating various biological phenomena in cell biology and drug discovery. Commercially available, mainly two class dyes, Nile Red (Greenspan et al. J. Lipid Res. T 985, 26, 781) and BODIPY derivatives (Spandl et al. Traffic 2009, 10, 1579; Chang, Y-T. et al. WO 2012/1 18444)- have been used for this purpose. Fluorescent probes fluorescein, BODIPY, rhodamine and cyanine
> are representative skeletons popularly used for various biosensors, discovery of novel fluorescent probes remains highly challenging.
Significance of lipid droplet markers in the area of kinetoplastid biology
In fungi and Kinetoplastid protozoans including Leishmania, ergosterol is the major storage lipid, and synthesized via type-2 fatty acid biosynthesis pathway. The biosynthesis pathway being unique to these organisms are thus targets by some of the major antifungal and anti- trypanosomal agents, such as ketoconazole, triclosan, miltefosine, amphotericin B. Studies have shown that Lysophospholipid analogues (LPAs) like edelfosine, ilmofosine and miltefosine interact with various sub-cellular structures and enzymes especially those associated with cellular membranes thus interfering with metabolism of membrane lipids. It has been reported that Leishmania infection induces lipid droplet accumulation in infected macrophages where Bodipy 493/503 has been used to visualize lipid droplet accumulation. L. donovani parasites, when undergoing stress tend to alter lipid metabolism and deposit more lipids in these lipid reservoirs. The size and number of LDs can be monitored using fluorescent markers. Recent findings linking LDs to the regulation and execution of immune responses in the context of host-pathogen interactions have been reviewed by Hector Alex Saka and Raphael Valdivia.
Markers can be used to visualize and quantify lipid droplets especially to study the effect of agents that interfere with lipid metabolism in kinetoplastid parasites like Leishmania and Trypanosoma. Commercially available lipid markers:
Commercially available common lipid markers are BODIPY, Nile Red, LipidTOX Red, LipidTOX Green, LipidTOX deep red, Monodansylpentane. The most widely used Nile Red dye has wide spectral occupancy and cannot be used with ranges of FITC, TRITC, Texas Red. BODIPY 493/503 is a FITC range dye with greater affinity to Lipid droplets and smaller fluorescent spectral footprint than Nile Red. A new lipid marker LD540 is a near red BODIPY family dye with excellent specificity but not available commercially (Thiele C. WO 201 1/018184) Lipid TOX dyes from Invitrogen are FITC compatible but very expensive (-200 times that of BODIPY 493/503). l ,6-Diphenyl-l,3,5-hexatrine (DPH) is only fluorescent in hydrophobic environment used for LD visualization with fluorescence microscopy but has not been very useful since it shares its excitation and emission properties with 4',6'-diamino-2-phenylindole (DAPI) and Hoechst stains.
In the present Invention novel donor-acceptor fluoranthenes have been prepared and investigated as fluorescent marker for staining neutral lipid droplets. Examples of some of these derivatives are mentioned here.
Synthesis of fluoranthene scaffolds:
Fluoranthene contain a rigid biphenyl structure locked into a coplanar arrangement by the presence of a fused benzene moiety. Few synthetic methodologies are available for the synthesis of fluoranthene derivatives, which mainly include the cycloaddition reaction of cyclopentadienone derivatives and alkynes or alkenes(Marcinow et al J. Org. Chem. 2002, 67, 3537; Viala et al J. Org. Chem. 2002, 4185; Wehmeier et al Chem. Eur. J. 2001, 7, 2197),Suzuki-Heck reaction of 1 -bromonaphthalene and 2 bromophenyl boronic acid (Wegner et al J. Org. Chem. 2003, 68, 883), reaction involving two triple bonds in 1 ,8- bis(phenylethynyl)-naphthalene under thermal or photochemical conditions(Wu et al J. Am. Chem. Soc. 2006, 128, 6870) or in the presence of metal catalysts such as .RhCl3-Aliquat 336, 1 ,4-palladium migration from 2-iodo-l-phenylnaphthalene(Campo et al J. Am. Chem. Soc. 2003, 125, 1 1506), reaction of propargylic alcohol bearing a fluorene moiety with diphenyl phosphine oxide(Onodera et al Org. Lett. 2005, 7, 4029) or benzoannulation reactions of □- oxoketene dithioacetals with various Grignard reagents(Jana et al Org. Lett. 2008, 10, 4795) or Pd-catalyzed electrocyclic reaction of a substituted acenaphthene. The present invention relates to a highly rapid novel synthesis of a new series of donor- acceptor fluoranthene systems.
OBJECTS OF THE INVENTION Main object of the present invention is to provide novel donor-acceptor fluoranthenes, having the general formula I.
Another object of the invention is to provide a process for the preparation of the novel donor- acceptor fluoranthene compounds having the general formula I.
Further object of the invention is to provide the compounds having the general formula I which are useful in preparing fluorescent dyes for cell imaging applications and other useful biological applications such as developing diagnostic kits.
SUMMARY OF THE INVENTION
Accordingly, the present invention provides a novel Donor-acceptor fluoranthenes having general formula I, and derivatives thereof
I
wherein R\ R RJ, R\ RJ, R°, R', R° are independently selected from the groups comprising hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or substituted acyloxy, unsubstituted or substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro; wherein the word "substituted" means substitution with a group selected from halogen(s), nitrile(s), ester(s), hydroxy(s), alkoxy(s), mercapto(s), carbontrifluoride(s), nitro(s), amino group(s) or Ci- to C2o-units; wherein X is a donor group comprising unsubstituted or substituted amine group, unsubstituted or substituted alkoxyl group, unsubstituted or substituted alkylthio group; wherein CN is a nitrile, an acceptor group.
In an embodiment of the present invention, the unsubstituted or substituted amine group is selected from amino, pyrrolidine, piperidine, methyl amine, ethyl amine, propyl amine, dimethylamine, N-alkylalkanolamine, Ν,Ν-dialkanolamine and pegylatedamine.
In another embodiment of the present invention, the representative compounds include;
i. 8-(dimethylamino)-10-isopropylfluoranthene-7-carbonitrile;
ii. 10-Phenyl-8-(pyrrolidin-l-yl)fluoranthene-7-carbonitrile;
iii. 10-(4-Methoxyphenyl)-8-(piperidin- 1 -yl)fluoranthene-7-carbonitrile;
iv. 8-(piperidin- 1 -yl)- 10-(thiophen-2-yl)fluoranthene-7-carbonitrile;
v. 10-(benzo[d][l ,3]dioxol-5-yl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile;
vi. 8-(piperidin- 1 -yl)- 10-(3,4,5-trimethoxyphenyl)fluorarithene-7-carbonitrile;
vii. 10-(4-nitrophenyl)-8-(piperidin- 1 -yl)fluoranthene-7-carbonitrile;
viii. 10-(4-hydroxyphenyl)-8-(piperidin- 1 -yl)fluoranthene-7-carbonitrile;
ix. 10-(3,4-dihydroxyphenyl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile;
x. 8-(piperidin-l-yl)-10-(3,4,5-trihydrsoxyphenyl)fluoranthene-7-carbonitrile;
xi. 10-(4-aminophenyl)-8-(piperidin- 1 -yl)fluoranthene-7-carbonitrile;
xii. 8-(bis(2-hydroxyethyl)amino)- 10-phenylfluoranthene-7-carbonitrile;
xiii. 8-((2-hydroxyethyl)(methyl)amino)-10-(4-methoxyphenyl)fluoranthene-7- carbonitrile;
xiv. 8-((2-hydroxyethyl)(methyl)amino)- 10-(4-methoxyphenyl)fluoranthene-7- carbonitrile;
xv. 8-((2-bromoethyl)(methyl)amino)- 10-(4-methoxyphenyl)fluoranthene-7- carbonitrile.
In another embodiment of the present invention, process for preparing donor-acceptor
(i) reacting a compound having general formula S-1 with a compound having general formula S-2 in an organic solvent in the presence of a base at a temperature ranging between -78°C to 100°C for a period ranging between 1 minute to 24 hr to obtain a reaction mixture wherein,
R1, R2, R3, R4, R5, R6, R7, R8 are independently selected from the groups comprising hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl, unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or substituted acyloxy, unsubstituted or substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro; wherein the word "substituted" means substitution 'with a group selected from halogen(s), nitrile(s), ester(s), hydroxy(s), alkoxy(s), mercapto(s), carbontrifluoride(s), nitro(s), amino group(s) or Cp to C2o-units;
wherein X is a donor group comprising unsubstituted or substituted amine, unsubstituted or substituted alkoxyl, unsubstituted or-substituted alkylthio group;
(ii) isolating and purifying the compound of general formula I from the reaction mixture.
In still an embodiment of the present invention, the organic solvent is selected from the group comprising DMF, THF, DMSO, DCM and isopropanol.
In yet another embodiment of the present invention, the base is selected from the group comprising KOH, NaOH, NaH, KH, K2C03 and Cs2C03
In one another embodiment of the present inventions use of donor-acceptor fluoranthenes having the general formula I alone or in combination with other fluorescent compounds and derivatives thereof for fluorescence-based cell imaging;
I
wherein R1, R2, R3, R4, R5, R6, R7, R8 are independently selected from the groups comprising hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or substituted acyloxy, unsubstituted or substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro;wherein the word "substituted" means substitution with a group selected from halogen(s), nitrile(s), ester(s), hydroxy(s), alkoxy(s), mercapto(s), carbontrifluoride(s), nitro(s), amino group(s) or Ci- to C20-units; wherein X is a donor group comprisingunsubstituted or substituted amine, unsubstituted or substituted alkoxyl, unsubstituted or substituted alkylthio group; wherein CN is an acceptor group.
In still yet another embodiment of the present invention, ¾aid fluorescence-based cell imaging or analysis is either a monocolor or a multi-color imaging or analysis.
In another embodiment of the present invention, a method for fluorescence-based imaging or analysis of cells and/or cellular components, comprising the following steps: i) staining cellular components with a donor-acceptor fluoranthenes having the general formula I, and derivatives thereof
wherein Rl , R2, R3, R4, R5, R6, R7, R8 are independently selected from the groups comprising of hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or substituted acyloxy, unsubstituted or substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro; wherein the word "substituted" means substitution 0f the moiety with a group selected from one or more halogen(s), nitrile(s), ester(s), hydroxy(s), alkoxy(s), mercapto(s), carbontrifluoride(s), nitro(s), amino group(s) or CI - to C20-units; wherein X is a donor group comprising of unsubstituted or substituted amino, unsubstituted or substituted alkoxyl, unsubstituted or substituted alkylthio group; wherein CN is an acceptor group; ii) exciting the fluoranthene dye of step i) with laser light in the wave length range from 405 nm to 665 nm;
iii) detecting the light emitted in step (ii);
iv) optionally, generating images with the emission data obtained in step iii);
v) optionally performing an analysis with the data obtained in step iii) or the images obtained in step iv).
In one another embodiment of the present invention, the cellular components stained with the fluoranthene dye of formula I in step i) are lipid droplets.
In still one another embodiment of the present invention, 1 , 2 or 3 other excitable fluorescent dye(s) are used, resulting in 2-color, 3-color or 4-color imaging.
In yet another embodiment of the present invention, living or fixed cells are subjected to said fluorescence-based imaging or analysis of cells and/or cellular components.
In still another embodiment of the present invention, a confocal 'laser scanning microscope, a spinning disc microscope, a two-photon microscope, a conventional epifluorescence microscope, a structured illumination microscope, or a single plane illumination microscope is used.
Even furthermore embodiment of the present invention relates to the compounds are prepared by reacting 2H-pyran-2-ones in isolated or rigid conformations with cyclic ketones containing methylene carbonyl moiety in the presence of a base in an organic solvent.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention may be more clearly understood by reference to the following Table/Figures:
Table 1 represents the photophysical properties of the compounds of the invention.
Table 2 represents the solvatochromic properties of compound 8.
Figure 1 illustrates the reaction sequence resulting in the preparation of various fluoranthene derivatives.
Figure 2 illustrates absorption, excitation and emission spectra of compound 1 in Water. Figure 3 illustrates absorption, excitation and emission spectra of compound 2 in Water. Figure 4 illustrates absorption, excitation and emission spectra of compound 3 in Water.. Figure 5 illustrates absorption, excitation and emission spectra of compound 4 in Water.
Figure 6 illustrates absorption, excitation and emission spectra of compound 5 in Water.
Figure 7 illustrates absorption, excitation and emission spectra of compound 6 in Water.
Figure 8 illustrates absorption, excitation and emission spectra of compound 8 in Water.
Figure 9 illustrates absorption, excitation and emission spectra of compound 9 in Water.
Figure 10 illustrates absorption, excitation and emission spectra of compound 10 in Water.
Figure 11 illustrates absorption, excitation and emission spectra of compound 11 in Water.
Figure 12 illustrates absorption, excitation and emission spectra of compound 12 in Water.
Figure 13 illustrates absorption, excitation and emission spectra of compound 13 in Water. Figure 14 illustrates absorption, excitation and emission spectra of compound 14 in Water.
Figure 15 illustrates absorption, excitation and emission spectra of compound 15 in Water.
Figure 16 Solvatochromism spectra of compound 8 in solvent of varying polarity.
Figure 17 illustrates excitation spectra of compound 8 with BODIPY and Nile Red dyes in water
Figure 18 illustrates emission spectra of compound 8 with BODIPY and Nile Red dyes in water.
Figure 19 illustrates L. donovani promastigotes stained with 300nM Nile Red in PBS for 10 min. in room temperature.
Figure 20 illustrates L. donovani promastigotes stained with lOOnM compound 8 in PBS for 2h in room temperature.
Figure 21 illustrates dual staining of L. donovani promastigotes with Nile Red and compound
8.
Figure 22 illustrates 3T3-L1 pre-adipocytes stained with 300nM Nile Red for 10 min at 37°C / 5% C02 in medium (DMEM).
Figure 23 illustrates 3T3-L1 pre-adipocytes were stained with lOOnm of compound 8 for 20 min. at 37°C / 5% C02 in medium (DMEM) on confocal dishes and directly analyzed by confocal microscopy.
Figure 24 illustrates dual staining of 3T3-L1 pre-adipocytes with Nile Red and compound 8. Figure 25 illustrates dual staining of 3T3-L1 pre-adipocytes with Hoeschst and compound 8. Figure 26 shows cell viability assessment of compound 8 in 3T3-L1 pre-adipocytes.
Figure 27 shows cell viability assessment of compound 8 in L. donovani promastigotes.
ABBREVIATIONS
LD: Lipid Droplets
BODIPY: Boron-dipyrromethene
FITC Fluorescein isothiocyanate
DPH 1 ,6-Diphenyl- 1 ,3,5-hexatrine
DAPI 4',6'-diamino-2-phenylindole
PBS Phosphate buffered saline
DMEM Dulbecco's Modified Eagle's Medium
TRITC Tetramethylrhodamine isothiocyanate
DIC Differential Interference Contrast
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to novel donor-acceptor fluoranthenes of the general formula I which can be used potentially in developing fluorescent probes, and a process of preparing said novel compounds. More particularly, the present invention relates to amine or alkoxy group as donor and nitrile group as an acceptor attached to the fluoranthene skeleton, processes for preparing the said compounds and their uses as fluorescent probes in chemical and biological sciences such as cell imaging applications, diagnostics, fluorescent tags and other useful applications.
The term 'fluorescent probe' refers to a fluorophore, which may be used to localize within a specific region of a biological specimen or to respond to a specific analyte/substance.
The term 'fluorescent tag' refers to a fluorescent molecule that is attached chemically to aid in the labeling and detection of a biomolecule such as a protein, antibody, or amino acid.
The present invention more p und of formula I:
I
(a) wherein R1, R2, R3, R4, R5, R6, R7, R8 are independently selected from the groups consisting of hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl unsubstituted
or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or substituted acyloxy, unsubstituted or substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro;
(b) wherein X is a donor group consisting of unsubstituted or substituted amino, unsubstituted or substituted alkoxyl, unsubstituted or substituted alkylthio group
(c) wherein the word "substituted" means substitution with one or more halogen(s), nitrile(s), ester(s), hydroxy(s), alkoxy(s), mercapto(s), carbontrifluoride(s), nitro(s), amino group(s) or
C|- to C20-units.
In another embodiment of the invention wherein the representative compounds comprising; i. 8-(Dimethylamino)-10-isopropylfluoranthene-7-carbonitrile (1).
ii. 10-Phenyl-8-(pyrrolidin-l-yl)fluoranthene-7-carbonitrile j(2).
iii. 10-(4-Methoxyphenyl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile (3).
iv. 8-(Piperidin- 1 -yl)- 10-(thiophen-2-yl)fluoranthene-7-carbonitrile (4).
v. 10-(Benzo[d][l ,3]dioxol-5-yl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile (5).
vi. 8-(Piperidin-l-yl)-10-(3,4,5-trimethoxyphenyl)fluoranthene-7-carbonitrile (6).
vii. 10-(4-Nitrophenyl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile (7).
viii. 10-(4-Hydroxyphenyl)-8-(piperidin- 1 -yl)fluoranthene-7-carbonitrile (8).
ix. 10-(3,4-Dihydroxyphenyl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile (9).
x. 8-(Piperidin- 1 -yl)- 10-(3,4,5-trihydroxyphenyl)fluoranthene-7-carbonitrile (10).
xi. 10-(4-Aminophenyl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile (1 1).
xii. 8-(Bis(2-hydroxyethyl)amino)-l 0-phenylfluoranthene-7-carbonitrile (12).
xiii. 8-((2-Hydroxyethyl)(methyl)amino)- 10-(4-methoxyphenyl)fluoranthene-7-carbonitrile (13)
xiv. 8-((2-Hydroxyethyl)(methyl)amino)- 10-(4-methoxyphenyl)fluoranthene-7- carbonitrile (14)
xv. 8-((2-Bromoethyl)(methyl)amino)- 10-(4-methoxyphenyl)fluoranthene-7-carbonitrile (15)
Accordingly the present invention provides a process for the preparation of novel donor- acceptor fluoranthene of the general formula I as shown in drawing accompanying the specification represents a preferred embodiment of this process:
I reacting a compound having general formula S-1 with a compound having general formula S-2 to furnish a compound having the general formula I
wherein R1, R2, R3, R4, R5, R6, R7, R8 are independently selected from the groups consisting of hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl, unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted ;or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or substituted acyloxy, unsubstituted or substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro;
Wherein X is a donor group consisting of unsubstituted or substituted amino, unsubstituted or substituted alkoxyl, unsubstituted or substituted alkylthio group wherein, reaction may proceeds in a common organic solvent particularly DMF, THF, DMSO, DCM, isopropanol in the presence of a base particularly KOH, NaOH, NaH, KH, K2C03, Cs2C03 at a temperature ranging between -78°C to 100°C for a period ranging between 1 minute to 24 hr.,
wherein, isolating the compound of general formula I from the reaction mixture and purifying by chromatographic techniques;
d. The starting material of the general formula S-l and S-2 are known and the compound of the general formula S-l has been prepared by -the reaction of methyl 2- cyano/methoxycarbonyl-3, 3-di (methylsulfanyl) acrylate with substituted acetophenones under alkaline conditions in dry DMSO in high yields. Accordingly the present invention is to provide the compounds having the general formula I which are useful in preparing fluorescent probes for cell imaging applications and other useful biological applications such as developing diagnostic kits.
Synthesis:
EXAMPLES:
Following examples are given by way of illustration and should not construe the scope of the present invention.
General procedure for the synthesis of compounds (Examplel-7, 12, 14, 15): Synthesis of fluoranthenes dyes with an amine donor and a nitrile acceptor substituents is an independent reaction of methyl 2-cyano-3,3-bis(dimethylsulfanyl)acrylate with various ketone were carried out to afford 6-aryl-3-cyano-4-methylsulfanyl-2H-pyran-2-ones in good yields. A good leaving methylsulfanyl group was replaced with an amine to furnish 6-aryl-2-oxo-4- (amin-l-yl)-2H-pyran-3-carbonitriles in good yields. Further stirring an equimolar mixture of 6-aryl-2-oxo-4-(amin-l-yl)-2H-pyran-3-carbonitriles and 2H-acenaphthylen-l -one in the presence of NaH in dry THF for 10-20 min. at 25-27°C yielded 10-alkyl/aryl 8-(amin-l- yl)fluoranthene-7-carbonitrile in good yields.
General procedure for the synthesis of compounds (Example 8-10): Compound 10-(4- methoxyphenyl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile (Example 3) or 10- (benzo[d][l,3]dioxol-5-yl)-8-(piperidin-l -yl)fluoranthene-7-carbonitrile (Example 5) or 8- (piperidin-l-yl)-10-(3,4,5-trimethoxyphenyl)fluoranthene-7-carbonitrile (Example 6) (1 mmol, lequiv.) was dissolved in dry CH2CI2 (10 ml) and BBr3 (2 equiv. or 4 equiv. or 6 equiv. respectively) was added to the solution at -78°C. The reaction mixture was stirred for 50 min at -78°C and then 10-15 hours at room temperature. After completion, the reaction mixture was quenched with ice-cooled water and neutralized with 10% HCL The reaction mixture was then extracted with CH2C12 and the organic layer separated, washed with brine, dried over
anhydrous Na2S04, and concentrated. The residue was purified by silica gel column chromatography using methanol in chloroform as the eluent to afford good yields of 10-(4- hydroxyphenyl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile (Example 8) or 10-(3,4- dihydroxyphenyl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile (Example 9) or 8-(piperidin- l-yl)-10-(3,4,5-trihydroxyphenyl)fluoranthene-7-carbonitrile (Example 10) respectively.
General procedure for the synthesis of compounds (Example 11): 10-(4-nitrophenyl)-8- (piperidin-l-yl)fluoranthene-7-carbonitrile (431 mg, 1 mmol, 1 equiv.) in isopropanol (5 mL) was reflux at 80°C for 1 hr. with Sn/HCl. The progress of the reaction was monitored by TLC and on completion solvent was evaporated and the reaction mixture was poured onto crushed ice with vigorous stirring and finally neutralized with dilute sodium bicarbonate solution. The precipitate obtained was filtered and purified on a silica gel column with 5% methanol in chloroform as the eluent to afford 318 mg (79%) as a yellow solid.
EXAMPLE-1
8-(Dimethylamino)- 10-isopropylfluoranthene-7-carbonitrile ( 1 )
A mixture of 4-(dimethylamino)-6-isopropyl-2-oxo-2H-pyran-3-carbonitrile (206 mg, 1 mmol, 1 equiv.), acenaphthylen- 1 (2H)-one (168 mg, 1 mmol, 1 equiv.), and NaH(60% dispersion in oil, 60 mg, 1.5 mmol, 1.5 equiv.) in dry THF (5 mL) was stirred at 25°C for 15 min. The progress of the reaction was monitored by TLC and on completion solvent was evaporated and the reaction mixture was poured onto crushed ice with vigorous stirring and finally neutralized with 10% HC1. The precipitate obtained was filtered and purified on a silica gel column with 2% ethyl acetate in hexane as the eluent to afford 250 mg (80%) as a yellow solid; Rf = 0.51 (n-hexane/ethyl acetate, 9: 1, v/v); mp (n-hexane/ethyl acetate) 208- 210 °C; MS (ESI) 313 [M + H+]; 1H NMR (300 MHz, CDC13)□□= 1.46 (d, J= 6.8 Hz, 6H, 2CH3), 3.14 (s, 6H, 2CH3), 3.80-3.95 (m, 1H, CH), 6.86 (s, l.H, ArH), 7.57-7.74 (m, 2H, ArH), 7.81 (d, J= 8.2 Hz 1H, ArH), 7.88-7.99 (m, 2H, ArH), 8.65 (d, J= 7.1 Hz, 1H, ArH) ppm.
EXAMPLE-2
10-Phenyl-8-(pyrrolidin- 1 -yl)fluoranthene-7-carbonitrile (2)
A mixture of 2-oxo-6-phenyl-4-(pyrrolidin-l-yl)-2H-pyran-3-carbonitrile (266 mg, 1 mmol, 1 equiv.), acenaphthylen-l(2H)-one (168 mg, 1 mmol, 1 equiv.), and NaH (60% dispersion in oil, 60 mg, 1.5 mmol, 1.5 equiv) in dry THF (5 mL) was stirred at 27°C for 12 min. The progress of the reaction was monitored by TLC and on completion solvent was evaporated and the reaction mixture was poured onto crushed ice with vigorous stirring and finally neutralized with 10% HC1. The precipitate obtained was filtered and purified on a silica gel column with 2% ethyl acetate in hexane as the eluent to afford 305 mg (82%) as a yellow solid; Rf = 0.48 (n-hexane/ethyl acetate, 9: 1, v/v); mp (n-hexane/ethyl acetate) 188-190 °C; MS (ESI) 373[M + H+]; Ή NMR (300 MHz, CDC13): δ= 2.00-2.1 1 (m, 4H, 2CH2), 3.71-3.83 (m, 4H, 2CH2), 6.52 (s, 1H, ArH), 6.98 (d, J= 7.0 Hz, 1H, ArH), '7.32' (t, J= 7.7 Hz, 1H, ArH), 7.50-7.59 (m, 5H, ArH), 7.65-7.75 (m, 2H, ArH), 7.90 (d, J= 8.1 Hz, 1H, ArH), 8.73 (d, J= 7.1 Hz, 1H, ArH).
EXAMPLE-3
10-(4-Methoxyphenyl)-8-(piperidi - 1 -yl)fluoranthene-7-carbonitrile (3)
A mixture of 6-(4-methoxyphenyl)-2-oxo-4-(piperidin-l-yl)-2H-pyran-3-carbonitrile (310 mg, 1 mmol, 1 equiv.), acenaphthylen-l (2H)-one (168 mg, 1 mmol, 1 equiv.), and NaH(60% dispersion in oil, 60 mg, 1.5 mmol, 1.5 equiv.) in dry THF (5 mL) was stirred at 25°C for 15 min. The progress of the reaction was monitored by TLC and on completion solvent was evaporated and the reaction mixture was poured onto crushed ice with vigorous stirring and
finally neutralized with 10% HC1. The precipitate obtained was filtered and purified on a silica gel column with 3% ethyl acetate in hexane as the eluent to afford 352 mg (84%) as a yellow solid; Rf = 0.49 (n-hexane/ethyl acetate, 9:1, v/v); mp (n-hexane/ethyl acetate) 242- 244 °C; MS (ESI) 417 [M + H+]; Ή NMR (300 MHz, CDC13)□□= 1.59-1.68 (m, 2H, CH2), 1.82-1.92 (m, 4H, 2CH2), 3.22-3.33 (m, 4H, 2CH2), 3.94 (s, 3H, CH3), 6.82 (s, 1H, ArH), 7.08 (d, J= 8.4 Hz, 2H, ArH), 7.20-7.31 (m, 1H, ArH), 7.25 (t, J= 7,6 Hz, 1H, ArH), 7.52 (d, J= 8.4 Hz, 2H, ArH), 7.67-7.80 (m, 2H, ArH), 7.92 (d, J= 8.1 Hz, IH, ArH), 8.66 (d, J= 7.1 Hz, lH, ArH) ppm.
EXAMPLE-4
8-(Piperidin- 1 -yl)- 10-(thiophen-2-yl)fluoranthene-7-carbonitrile (4)
A mixture of 2-oxo-4-(piperidin-l-yl)-6-(thiophen-2-yl)-2H-pyran-3-carbonitrile (286 mg, 1 mmol, 1 equiv.), acenaphthylen-l(2H)-one (168 mg, 1 mmol, 1 equiv.), and NaH(60% dispersion in oil, 60 mg, 1.5 mmol, 1.5 equiv.) in dry THF (5 mL) was stirred 27°C for 15 min. The progress of the reaction was monitored by TLC and on completion solvent was evaporated and the reaction mixture was poured onto crushed ice with vigorous stirring and finally neutralized with 10% HC1. The precipitate obtained was filtered and purified on a silica gel column with 2% ethyl acetate in hexane as the eluent to afford 305 mg (78%) as a yellow solid; Rf = 0.53 (n-hexane/ethyl acetate, 9: 1 , v/v); mp (n-hexane/ethyl acetate) 246- 248 °C; MS (ESI) 393 [M + H+]; Ή NMR (300 MHz, CDC13)□□= 1.60-1.70 (m, 2H, CH2), 1.80-1.91 (m, 4H, 2CH2), 3.24-3.32 (m, 4H, 2CH2), 6.94 (s, IH, ArH), 7.20-7.27 (m, 2H, ArH), 7.34-7.40 (m, IH, ArH), 7.41-7.47 (m, IH, ArH), 7.50-7.55 (m, IH, ArH), 7.69-7.83 (m, 2H, ArH), 7.94 (d, J= 8.2 Hz, IH), 8.67 (d, J= 7.1 Hz, IH, ArH) ppm.
EXAMPLE S
A mixture of 6-(benzo[< ][l ,3]dioxol-5-yl)-2-oxo-4-(piperidin-l-yl)-2H-pyran-3-carbonitrile (324 mg, 1 mmol, 1 equiv.), acenaphthylen-l(2H)-one (168 mg, 1 mmol, 1 equiv.), and NaH(60% dispersion in oil, 60 mg, 1.5 mmol, 1.5 equiv.) in dry THF (5 mL) was stirred at
[) 25°C for 12 min. The progress of the reaction was monitored by TLC and on completion solvent was evaporated and the reaction mixture was poured onto crushed ice with vigorous stirring and finally neutralized with 10% HC1. The precipitate obtained was filtered and purified on a silica gel column with 3% ethyl acetate in hexane as the eluent to afford 318 mg (74%) as a yellow solid; Rf = 0.48 (n-hexane/ethyl acetate, 9: 1 , v/v); mp (n-hexane/ethyl
5 acetate) 244-246 °C; MS (ESI) 431 [M + H+]; Ή NMR (300 MHz, CDC13)□□= 1.62-1.68 (m, 2H, CH2), 1.83-1.88 (m, 4H, 2CH2), 3.23-3.32 (m, 4H, 2CH2), 6.10 (s, 2H, CH2), 6.81 (s, 1H, ArH), 6.97-7.10 (m, 1H, ArH), 7.26-7.35 (m, 2H, ArH), 7.68-7.78 (m, 1H, ArH), 7.42 (t, J= 7.6 Hz, 1H, ArH), 7.66-7.81 (m, 2H, ArH), 7.93 (d, J= 8.1 Hz, 1H, ArH), 8.67 (d, J= 7.1 Hz, 1H, ArH) ppm.
EXAMPLE-6
8-(Piperidin-l-yl)-10-(3,4,5-trimethoxyphenyl)fluoranthene-7-carbonitrile (6)
A mixture of 2-oxo-4-(piperidin-l-yl)-6-(3,4,5-trimethoxyphenyl)-2H-pyran-3-carbonitrile (370 mg, 1 mmol, 1 equiv.), acenaphthylen-l(2H)-one (168 mg, 1 mmol, 1 equiv.), and NaH(60% dispersion in oil, 60 mg, 1.5 mmol, 1.5 equiv.) in dry THF (5 mL) was stirred at 25°C for 10 min. The progress of the reaction was monitored by TLC and on completion ) solvent was evaporated and the reaction mixture was poured onto crushed ice with vigorous
5 stirring and finally neutralized with 10% HCI. The precipitate obtained was filtered and purified on a silica gel column with 5% ethyl acetate in hexane as the eluent to afford 348 mg (73%) as a yellow solid; Rf = 0.43 (n-hexane/ethyl acetate, 9: 1, v/v); mp (n-hexane/ethyl acetate) 240-245 °C; MS (ESI) 477 [M + H+]; Ή NMR (300 MHz, CDC13)□□= 1.62-167 (m, 2H, CH2), 1.84-188 (m, 4H, 2CH2), 3.25-3.32 (m, 4H, 2CH2), 3.88 (s, 6H, 2CH3), 3.99 (s,
0 3H, CH3), 6.79 (s, 1H, ArH), 6.86 (s, 1H, ArH), 7.14 (t, J= 7.6 Ήζ, 1H, ArH), 7.68-7.78 (m, 2H, ArH), 7.94 (d, J= 8.1 Hz, 1H, ArH), 8.67 (d, J= 7.0 Hz, 1H, ArH) ppm.
EXAMPLE-7
10-(4-Nitrophenyl)-8-(piperidin- 1 -yl)fluoranthene-7-carbonitrile;(7).
A mixture of 6-(4-nitrophenyl)-2-oxo-4-(piperidin- l-yl)-2H-pyran-3-carbonitrile (325 mg, l mmol, l eq.), acenaphthylen- 1 (2H)-one (168 mg, 1 mmol, 1 equiv.), and NaH(60% dispersion in oil, 60 mg, 1.5 mmol, 1.5 equiv.) in dry THF (5 mL) was stirred at 25°C for 15
) min. The progress of the reaction was monitored by TLC and on completion solvent was evaporated and the reaction mixture was poured onto crushed ice with vigorous stirring and finally neutralized with 10% HCI. The precipitate obtained was filtered and purified on a silica gel column with 2% ethyl acetate in hexane as the eluent to afford 348 mg (81%) as an orange solid; Rf = 0.53 (n-hexane/ethyl acetate, 9: 1 , v/v); mp (n-hexane/ethyl acetate) >250 °C; MS (ESI) 432 [M + H+]; Ή NMR (300 MHz, CDC13)□□= 1.62-1.73 (m, 2H, CH2), 1.80- 1.93 (m, 4H, 2CH2), 3.30 (t, J= 5.3 Hz, 4H, 2CH2), 6.80 (s, 1H, ArH), 7.06 (d, J= 7.1 Hz, ArH), 7.39 (t, J= 7.7 Hz, 1H, ArH), 7.71-7.84 (m, 4H, ArH), 8:00 (d, J= 8.2 Hz, 1H, ArH), 8.43 (d, J= 8.6 Hz, 2H, ArH), 8.70 (d, J= 7.1 Hz, 1 H, ArH) ppm.
) EXAMPLE-8
10-(4-Methoxyphenyl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile (416mg, 1 mmol, lequiv.) was dissolved in dry CH2C12 (10 ml) and BBr3 (192 DL, 2 mmol, 2 equiv.) was added to the solution at -78°C. The reaction mixture was stirred for 50 min at -78°C and then 10 hours at 25°C. After completion, ^the reaction mixture was quenched with ice-cooled water and neutralized with 10% HCl. The reaction mixture was then extracted with CH2C12 and the organic layer separated, washed with brine, dried over anhydrous Na2S04, and concentrated. The residue was purified by silica gel column chromatography using 1 % methanol in chloroform as the eluent to afford 312mg (78%) as yellow solid; Rf = 0.59 (chloroform/methanol, 9:1 , v/v); mp (chloroform/methanol) >250 °C; MS (ESI) 403 [M +
H+]; Ή NMR (300 MHz, CDC13)□□= 1.62-1.68 (m, 2H, CH2), 1.79-1.91 (m, 4H, 2CH2), 3.23-3.31 (m, 4H, 2CH2), 5.10 (s, 1H, OH), 6.82 (s, 1H ArH), 7.02 (d, J= 8.5 Hz, 2H, ArH), 7.20-7.24 (m, 1H, ArH), 7.39 (t, J= 8.1 Hz, 1H, ArH), 7.47 (d, J= 8.5 Hz, 2H, ArH), 7.70- 7.79 (m, 2H, ArH), 7.93 (d, J= 8.2 Hz, 1H, ArH), 8.66 (d, J= 7.2 Hz, 1H, ArH) ppm.
EXAMPLE-9
10-(3,4-dihydroxyphenyl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile (9)
10-(benzo[d][l,3]dioxol-5-yl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile (430mg, 1 mmol, lequiv.) was dissolved in dry CH2C12 (10 ml) and BBr3 (384 DL, 4 mmol, 4 equiv.) was added to the solution at -78°C. The reaction mixture was stirred for 50 min at -78°C and then 12 hours at 25°C. After completion, the reaction mixture was quenched with ice-cooled water and neutralized with 10% HCl. The reaction mixture was then extracted with CH2C12 and the organic layer separated, washed with brine, dried over anhydrous Na2S04, and concentrated.
The residue was purified by silica gel column chromatography using 1% methanol in chloroform as the eluent to afford 297mg (72%) yield as yellow solid; Rf = 0.51 (chloroform/methanol, 9: 1 , v/v); mp (chloroform/methanol) 244-246 °C; MS (ESI) 419 [M + H+]; Ή NMR (300 MHz, DMSO-d6)□□= 1.59-164 (m, 2H, CH2), 1.74-1.78 (m, 4H, 2CH2), 3.24-3.27 (m, 4H, 2CH2), 6.85 (m, 4H, ArH), 7.40 (d, J= 6.9 Hz, IH, ArH), 7.56 (t, J= 7.6 Hz, IH, ArH), 7.85 (t, J= 7.7 Hz, I H, ArH), 7.93 (d, J= 8.1 Hz, IH, ArH), 8.1 1 (d, J= 8.2 Hz, IH, ArH), 8.53 (d, J= 7.1 Hz, IH, ArH), 9.23 (s, IH, -OH), 9.29 (s, IH, OH) ppm.
EXAMPLE-10
8-(Piperidin-l-yl)-10-(3,4,5-trihydroxyphenyl)fluoranthene-7-carbonitrile (10)
Compound 8-(piperidin- 1 -yl)- 10-(3,4,5-trimethoxyphenyl)fluoranthene-7-carbonitrile
(476mg, 1 mmol,leq.) was dissolved in dry CH2C12 (10 ml) and BBr3 (576D DL, 6 mmol, 6 equiv) was added to the solution at -78°C. The reaction mixture was stirred for 50 min at - 78°C and then 15 hours at 25°C. After completion, the reaction mixture was quenched with ice-cooled water and neutralized with 10% HCl. The reaction mixture was then extracted with CH2C12 and the organic layer separated, washed with brine, dried over anhydrous Na2S04, and concentrated. The residue was purified by silica gel column chromatography using 5% methanol in chloroform as the eluent to afford 292 mg (69%) as yellow solid; Rf = 0.47 (chloroform/methanol, 9: 1 , v/v); mp (chloroform/methanol) 238-240 °C; MS (ESI) 435 [M + H+]; 'H NMR (300 MHz, DMSO-d6)□□= 1.58-1.78 (m, 2H, CH2), 1.74-1.78 (m, 4H, 2CH2), 3.23-3.27 (m, 4H, 2CH2), 6.53 (s, 2H, ArH), 6.87 (s, IH, ArH), 7.45-7.51 (m, IH, ArH), 7.58 (t, J= 7.3 Hz, IH, ArH), 7.85 (t, J= 7.5 Hz, IH, ArH), 7.94 (d, J= 8.0 Hz, IH, ArH), 8.12 (d, J= 7.7 Hz, IH, ArH), 8.47 (s, IH, -OH) 8.52 (d, J= 6.9 Hz, IH, ArH), 9.16 (s, 2H, -20H) ppm.
EXAMPLE-11
10-(4-nitrophenyl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile (431 mg, 1 mmol, 1 equiv.) in isopropanol (5 mL) was reflux at 80°C for 1 hr. with Sn HCl. The progress of the reaction was monitored by TLC and on completion solvent was evaporated and the reaction mixture was poured onto crushed ice with vigorous stirring and finally neutralized with dilute sodium bicarbonate solution. The precipitate obtained was filtered and purified on a silica gel column with 5% methanol in chloroform as the eluent to afford 318 mg (79%) as a yellow solid; Rf = 0.51 (chloroform/methanol, 9: 1, v/v); mp (chloroform/methanol) 232-234 °C; MS (ESI) 402 [M + H+]; 1H NMR (300 MHz, DMSO-d6)□□= 1.51-1.58 (m, 2H, CH2), 1.67-1.71(m, 4H, 2CH2), 3.14-3.21 (m, 4H, 2CH2), 5.42 (s, 2H, NH2), 6.69 (d, J= 8.4 Hz, 2H, ArH), 6.80 (s, 1H, ArH), 7.27 (d, J= 8.3 Hz, 2H, ArH), 7.38-7.53 (m, 2H, ArH), 7.77 (t, J= 7.7 Hz, 1H, ArH), 7.86 (d, J= 7.9 Hz, 1H, ArH), 8.03 (d, J= 8.1 Hz, 1H, ArH), 8.45 (d, J= 7.1 Hz, 1H, ArH) ppm.
EXAMPLE-12
8-(Bis(2-hydroxyethyl)amino)- 10-phenylfluoranthene-7-carbonitrile ( 12)
A mixture of 4-(bis(2-hydroxyethyl)amino)-2-oxo-6-phenyl-2H-pyran-3-carbpnitrile (300 mg, 1 mmol, 1 equiv.), 2H-acenaphthylen-l-one (168 mg, 1 mmol, 1 equiv.), and NaH (60% dispersion in oil, 60 mg, 1.5 mmol, 1.5 equiv.) in dry DMF (5 mL) was stirred at 22°C for 12 min. The progress of the reaction was monitored by TLC and on completion solvent was evaporated and the reaction mixture was poured onto crushed ice with vigorous stirring and finally neutralized with 10% HC1. The precipitate obtained was filtered and purified on a
silica gel column using 5% methanol in chloroform as the eluent to afford 276 mg (68%) as yellow solid; Rf = 0.48 (chloroform/methanol, 9: 1 , v/v); mp (chloroform/methanol) 1 10-1 12 °C; MS (ESI) 407 [M + H+]; Ή NMR (300 MHz, DMSO-d6): δ = 3.53-3.71 (m, 8H, 4CH2), 4.68 (t, = 4.9 Hz, 2H, OH), 6.92 (s, IH, ArH), 7.00 (d, J= 7.1 Hz, IH, ArH), 7.39 (t, J= 7.7 Hz, IH, ArH), 7.53 (s, 5H, ArH), 7.71-7.92 (m, 2H, ArH), 8.01 (d, J= 8.1 Hz, IH, ArH), 8.50 (d, J= 8.1 Hz, IH, ArH).
EXAMPLE-13
10-(4-(Heptyloxy)phenyl)-8 nitrile (13)
A mixture of 10-(4-hydroxyphenyl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile (402 mg, lmmol, leq.), 1 -bromoheptane (178 mg, 1 mmol, 1 equiv.), and NaH(60% dispersion in oil, 60 mg, 1.5 mmol, 1.5 equiv.) in DMF (5 mL) was stirred at 25°C for 1 hr. The progress of the reaction was monitored by TLC and on completion solvent was evaporated and the reaction mixture was poured onto crushed ice with vigorous stirring and finally neutralized with 10% HC1. The precipitate obtained was filtered and purified on a silica gel column with 2% ethyl acetate in hexane as the eluent to afford 390 mg (78%) as yellow solid; R = 0.59 (n- hexane/ethyl acetate, 9: 1, v/v); mp (n-hexane/ethyl acetate) >250 °C; MS (ESI) 501 [M + H+]; 1H NMR (400 MHz, CDC13)□□= 0.92 (t, j= 6.1 Hz, 3H, CH3), 1.24-1.62 (m, 10H, 5CH2), 1.84-1.87 (m, 6H, 3CH2), 3.27 (t, J- 4.9 Hz,4H, 2CH2), 4.07 (t, J= 6.5 Hz, 2H, CH2), 6.82 (s, IH, ArH), 7.1(d, J= 8.4 Hz, 2H, ArH), 7.23-7.26 (m, IH, ArH), 7.38(t, J= 7.6 Hz, IH, ArH), 7.67-7.78(m, 2H, ArH), 7.92 (d, J= 8.1 Hz, IH, ArH), 8.7 (d, J= 7.1 Hz, IH, ArH) ppm.
EXAMPLE-14
A mixture of 4-((2-hydroxyethyl)(methyl)amino)-6-(4-methoxyphenyl)-2-oxo-2H-pyran-3- carbonitrile (300 mg, 1 mmol, 1 equiv.), acenaphthylen- 1 (2H)-one (168 mg, 1 mmol, 1 equiv.), and NaH(60% dispersion in oil, 60 mg, 1.5 mmol, 1.5. equiv.) in dry DMF (5 mL)
D was stirred at 25°C for 20 min. The progress of the reaction was monitored by TLC and on completion solvent was evaporated and the reaction mixture was?poured onto crushed ice with vigorous stirring and finally neutralized with 10% HC1. The precipitate obtained was filtered and purified on a silica gel column with 5% ethyl acetate in hexane as the eluent to afford 280 mg (68%) as a yellow solid; Rf = 0.45 (n-hexane/ethyl acetate, 9: 1 , v/v); mp (n-hexane/ethyl
5 acetate) 242-244 °C; MS (ESI) 407 [M + H+]; Ή NMR (400 MHz, CDC13)□□= 3.09 (s, 3H, CH3), 3.55 (t, J- 5.7 Hz, 2H, CH2),3.92-4.01(m, 5H, CH2, OCH3), 6.90 (s, IH, ArH), 7.03- 7.1 1 (m, 2H, ArH), 7.22-7.28 (m, 2H. ArH), 7.39 (t, J= 7.6 Ηζ,Π Η, ArH), 7.49-7.55 (m, 2H, . ArH), 7.69-7.78 (m, 2H, ArH), 7.94 (d, J= 8.1 Hz, IH, ArH), 8.66 (d, J= 7.0 Hz, IH, ArH) ppm.
3 . . ■> ■ ': .' ·■ , .. · EXAMPLE-15
8-((2-Bromoethyl)(methyl)amino -10-(4-methoxyphenyl)fluoranthene-7-carbonitrile (15)
5 A mixture of 8-((2-hydroxyethyl)(methyl)amino)-10-(4-methoxyphenyl)fluoranthene-7- carbonitrile (406 mg, 1 mmol, 1 equiv.) and POBr3 (339 mg, 1.2 mmol) was refluxed in presence of Cs2C03 in dry toluene for l -3h. The progress of the reaction was monitored by TLC and after completion; the excess toluene was removed under vacuum. Crude product was purified by silica gel column chromatography using 2% ethyl acetate in hexane as the eluent
) to afford 335 mg (71%) as a yellow solid; Rf = 0.56 (n-hexane/ethyl acetate, 9: 1 , v/v); mp (n-
hexane/ethyl acetate) 242-244 °C; MS (ESI) 469 [M + H+]; Ή NMR (400 MHz, CDC13) δ = 3.13 (s, 3H, CH3), 3.66-3.72 (m, 2h, CH2), 3.87 (t, J= 7.4 Hz, 2H, CH2), 3.94 (s, 3H, CH3), 6.83 (s, 1H, ArH), 7.06-7.1 l(m, 2H, ArH), 7.22-7.27 (m, 1H. ArH), 7.38-7.43 (m, 1H, ArH), 7.49-7.55 (m, 2H, ArH), 7.69-7.78(m, 2H, ArH), 7.94 (d, J= 8.0 Hz, 1H, ArH), 8.68 (d, J= 7.0 Hz, Ι Η, ΑΓΗ).
Photophysical studies of the compounds of general formula I
The photophysical properties of all the synthesized compounds 1-15 were examined by UV-vis and fluorescence techniques (Figure 2-15). Table 1 showed the Dmax of their UV, excitation and fluorescence spectral data along with stoke's shift. These compounds produced different color emissions depending upon the nature and position of electron donor-acceptor substituents and chromophores attached on fluoranthene scaffolds (Table 1).
Table 1. Photophysical properties of fluoranthene (Examples 1-15) in 0.2% DMSO in Water.
compound 0 max; abs D max, ex 0 max, em Ass (nm)c Emission Colord
(nm)a (nm) (nm)b
1 330 330, 434 554 224 Y
218
2 332 330, 432 550 Y
3 328 335, 437 552 220 Y
4 340 338, 455 555 215 Y
5 327 330, 435 552 225 Y
6 332 332, 432 213 Y
545
8 330 332, 435 550 220 Y
9 336 332, 435 548 212 Y
10 333 335, 437 550 217 Y
11 336 337, 438 550 214 Y
12 335 330, 442 547 212 Y
13 332 335, 432 542 210 Υ
14 342 338, 440 552 210 Υ
15 338 332, 435 548 210 Υ
"Longest wavelength absorption maximum in 0.2% DMSO in Water, bFluorescence emission maximum at 405 nm excitation in 0.2% DMSO in Water, °Stokes shift in nm , dEmission colour in 0.2% DMSO in water. Y = Yellow, NF = No fluorescence.
Solvatochromism: Due to the difference in the dipole moments of the donor-acceptor molecules in the ground and excited states and their stabilization by polar or non-polar solvent molecules through various noncovalent interactions like hydrogen bonding, solvation or dipole-dipole interactions, novel donor-acceptor fluoranthenes exhibit solvatochromic behaviour as shown in Figure 16. The absorption and PL spectra of compound 8 were examined using solvents of varying polarity as depicted in Table 2.
Table 2. Photophysical analysis of compound 8 in various solvents. solvents ^•max;abs (nm) Stoke's
Shift (cm 1)
Cyclohexane 331 527 1 1230
Toluene 332 530 1 1250
Dioxane 332 540 1 1600
Dichloromethane 331 545 1 1860
Water 330 550 1 1940
Ethanol 330 548 12050
Methanol 331 554 12160
Acetonitrile 330 569 12730
DMF 332 573 12690
DMSO 333 580 12790
Excitation and emission spectra of compound 8 with Nile Red and BODIPY dyes.
Excitation and emission spectra of compound 8 were examined with commercially available lipid droplet probes (Nile Red and BODIPY) in 0.2 % DMSO in water as shown in drawing accompanying the specification (Figure 17 and Figure 18). An excitation maximum of compound 8 was observed at 332 nm and 435 nm. Excitation maxima of BODIPY and Nile Red were observed at 493 and 597 nm respectively while emission maxima of these fluorescent probes were 550, 503 and 657 nm respectively. On comparison of Ex/Em range of these dyes with compound 8, novel fluoranthene dye showed different emission window and high stokes shift compare to the commercially available BODIPY and Nile Red dyes and therefore, it can be used in multicolor live cell imaging without background noise.
Dyes Ex/Em max Application
Nile Red 485/525-636 Staining of neutral lipid
Lipid TOX Red 577/609 Neutral lipid staining in HCS
Lipid TOX Green 495/505 Neutral lipid staining in HCS
Lipid TOX deep red 637/655 Neutral lipid. staining in HCS
BODIPY 493/503 LD staining
Monodansylpentane 405/480 Neutral Lipid droplet Staining compound 8 405/550 Neutral LD staining Biological Evaluation:
Cell Culture of 3T3-L1 Preadipocytes
3T3-L1 pre-adipocyte cells were obtained earlier from American Type Culture Collection, Manassas, VA, Cat. No. CL-173 and maintained in the tissue and cell culture facility at CDRI, Lucknow. 3T3-L1 pre-adipocytes were cultured in DMEM with 10% heat-inactivated
5 FBS at 37°C. After reaching 70% confluence, cells were seeded two days before starting experiments. Leishmania donovani (strain MHOM/IN/80/Dd8) promastigotes were cultured as described previously (Nayak, R. C; Sahasrabuddhe, A. A.; Bajpai, V. K.; Gupta, C. M.; Mol. Biochem. Parasitol. 2005, 143, 152.). Briefly, cells were cultured in Dulbecco's Modified Eagles Medium (DMEM) with phenol red, L-glutamine and 4.8g/L D-glucose
D supplemented with 10% heat inactivated FBS and sodium pyruvate. Cell were checked for their health periodically and maintained in standard tissue culture flasks. After reaching an approximate density of 106cells/ml they were prepared for incubation.
Cell Culture of Leishmania donovani:
5
Leishmania donovani (strain MHOM/IN/80/Dd8) cells were obtained from Dr Sahasrabudhe, Molecular and Structural Biology division of the CDRI, Lucknow. These cells were cultured in Dulbecco's Modified Eagles Medium (DMEM) with phenol ;red, L-glutamine and 4.8g/L D-glucose supplemented with 10% heat inactivated FBS and sodium pyruvate. Cells were ) checked for their health periodically and maintained in standard tissue culture flasks. After reaching an approximate density of 106, they were prepared for incubation. 3T3-L1 pre- adipocytes were cultured in DMEM with 10% heat-inactivated FBS at 37°C. After reaching 70% confluence, cells were seeded and cultured for 2 days in confocal dishes before commencing experiments.
5
Confocal Microscopy:
L. donovani cells, briefly after harvesting, were incubated with ΙΟΟηΜ compound 8 for 1 hour (empirically determined) at room temperature. Afterwards, they were washed once in PBS (lx) and further incubated with either 300 nM Nile Red for 10 minutes. Cells were then
) adhered to poly-L-lysine coated coverslips and immediately processed for microscopic examination. 3T3-L1 pre-adipocytes adhered to confocal microscopic dishes were incubated with the dyes in media for 30 min. (empirically determined) at 37°C. They were washed and stained with Hoechst 33342 (Invitrogen) for 10 min. at room temperature before analyzing directly under the confocal microscope LSM 510 META (Carl Zeiss, Jena, Germany).
5 Objective used was a Plan Apochromat 60X or a 40* Ph/DIC objective.
5 Analysis:
The images saved from the microscope were analyzed with the LSM Image Examiner software (Carl Zeiss).
Fluorescence staining in Leishmania promastigotes with Nile Red:
3 L. donovani promastigotes stained with 300nM Nile Red in PBS for 10 min. at room temperature. Lipid droplets are indicated by distinct red spots scattered throughout the cell as indicated by arrows in Figure 19. Cells were imaged with a 63x Plan Apochromat Oil DIC 1.4 NA objective. Imaging experiments were performed at Excitation wavelength at 514 nm with Emission filter of 575nm Long Pass.
5
Fluorescence staining in Leishmania promastigotes with compound 8:
L. donovani promastigotes stained with ΙΟΟηΜ compound 8 in PBS for 2h at room temperature. Lipid droplets are indicated by orange spots as indicated by arrows in Figure 20 scattered throughout the cell. Bar indicates 5μπι. Imaging experiments were performed at ) Excitation wavelength at 405 nm with Emission filter of 530nm Long Pass.
Dual staining of Leishmania promastigotes with Nile Red and compound 8.
Figure 16 represents Dual staining of L. donovani promastigotes with Nile Red and compound 8. Cells were first incubated with compound 8 for 2h, then stained with Nile Red for 15 min at 5 room temperature. Bars indicate 5μιη. Imaging experiments were performed at Excitation wavelength at 514 nm for Nile Red and 405 nm for compound 8. Staining pattern is similar with Nile Red and compound 8 as indicated by arrows in Figure 21.
Fluorescence staining in 3T3-L1 pre-adipocytes with Nile Red:
) 3T3-L1 pre-adipocytes stained with 300nM Nile Red for 10 min. at 37°C/5%C02 in medium (DMEM). Cells were imaged with a 63x PlanApochromat Oil DIC 1.4 NA objective. Lipid droplets are distinctly stained as red dots throughout the cytoplasm as shown in Figure 22. Imaging experiments were performed at Excitation wavelength at 514 nm with Emission filter of 575nm Long Pass. Bars indicate 5μηι.
5 Fluorescence staining in 3T3-L1 pre-adipocytes with compound 8:
3T3-L1 pre-adipocytes were stained with lOOnm of compound 8 for 20 min. at 37°C/5%C02 in medium (DMEM) on confocal dishes and directly analyzed by confocal microscopy. Lipid droplets are distinctly stained as orange dots throughout the cytoplasm as shown in Figure 23. Imaging experiments were performed at Excitation wavelength at 405 nm with Emission filter 3 of 505-550 nm. Bars indicate 5μπι.
Dual staining of 3T3-L1 pre-adipocytes with Nile Red and compound 8.
Figure 24 represents Dual staining of 3T3-L1 pre-adipocytes with Nile Red and compound 8. Cells were first incubated with compound 8 for 2h, then stained with Nile Red for 15 min at 5 room temperature. Bars indicate 5μπι. Imaging experiments were performed at Excitation wavelength at 514 nm for Nile Red and 405 nm for compound 8. Staining pattern is similar with Nile Red.
Dual staining of 3T3-L1 pre-adipocytes with Hoechst 33342 and compound 8.
) Figure 25 represents Dual staining of 3T3-L1 pre-adipocytes with Hoechst 33342 and compound 8. Cells were first incubated with compound 8 for 2h, then stained with Hoechst 33342 for 10 min at room temperature. Bars indicate 5μιη. Imaging experiments were performed at Excitation wavelength at 405 nm for Hoechst 33342 and compound 8.
> Toxicity Assessment in 3T3-L1 pre-adipocytes and L. donovani promastigotes. 3T3-L1 cells were seeded a day before experiment in confocal coverglass bottom dishes (105 cells/dish). Afterwards, cells were treated with compound 8 at concentrations of Ι μΜ, 500nM, 250nM and ΙΟΟηΜ for 24hrs before staining with SYTOX® Green (500nM) for 15min. Samples were analyzed under the confocal microscope. Cells that had taken up the
) stain were counted in a random population of >500 cells and were considered dead. Viability from these concentrations of the fluorophore was compared with vehicular control (DMSO). Figure 26 represents cell viability assessment of compound 8 in 3T3-L1 pre-adipocytes.
L. donovani promastigotes were incubated with the compound 8 at different working concentrations (50nM, ΙΟΟηΜ, 5Q0nM and Ι μΜ) for the required incubation period of 3 hrs.
> Toxicity was determined by the resazurin assay (PrestoBlue® Cell Viability Reagent), as described previously (Fernandez-Checa, J. C; Biochem. Biophys. Res. Commun. 2003, 304, 471.). Resazurin is a blue non-fluorescent dye that is reduced to highly fluorescent resorufin
5 upon activity of mitochondrial enzymes in healthy cells. After incubation with the dye a 10% solution of PrestoBlue was added to the cells (106 cells/ml) and allowed to incubate further for 2 hrs away from light. Fluorescence was measured with a TEC AN Ml 000 monochromator based microplate reader. Figure 27 represents cell viability assessment of compound 8 in L. donovani promastigotes.
Results:
Staining pattern with compound 8 in 3T3-L1 pre-adipocytes and Leishmania promastigotes strongly suggested localization in lipid droplets similar to Nile Red staining (known to target
5 lipid droplets) To confirm this observation, dual staining experiments were also performed which clearly showed co-localization of the Nile Red and compound 8 within LDs. No labeling was found in nucleus and other organelles. In summary, a new class of live cell permeant, solvatochromic bioprobes compound 8 was identified, which exhibited strong and selective staining of intracellular lipid droplets in in vitro live 3T3-L1 pre-adipocytes, and in
) parasitic protozoa Leishmania donovani promastigotes. The live cell imaging studies clearly demonstrated that dye 8 is a specific and non-toxic lipid molecular bioprobe for quantification of lipid droplets with high brightness at a low concentration of 100 nM without background noise and is better than Nile red. Cell viability experiments revealed that Compound 8 showed no cytotoxicity in 3T3-L1 preadipocytes up to a concentration of 1 DM, where 93.5% cells ί were viable and in Leishmaniadonovani 99% of the cells were viable. Dye 8 exhibited clearly distinct PL from the commercially available BODIPY and Nile Red dyes and it may be used as a fluorescent probe alone or in combination with other fluorophores for multi-color imaging applications.
Claims
We claim:
1. Donor-acceptor fluoranthenes having general formula I, and derivatives thereof;
I
wherein R1, R2, R3, R4, R5, R6, R7, R8 are independently selected from the groups comprising hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or substituted acyloxy, unsubstituted or substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro; wherein the word "substituted" means substitution with a group selected from halogen(s), nitrile(s), ester(s), hydroxy(s), alkoxy(s), mercapto(s), carbontrifluoride(s), nitro(s), amino group(s) or Ci- to C2o-units; wherein X is a donor group comprising unsubstituted or substituted amine group, unsubstituted or substituted alkoxyl group, unsubstituted or substituted alkylthio group; wherein CN is a nitrile, an acceptor group.
2. The compound as claimed in claim 1 , wherein the unsubstituted or substituted amine group is selected from amino, pyrrolidine, piperidine, methyl amine, ethyl amine, propyl amine, dimethylamine, N-alkylalkanolamine, Ν,Ν-dialkanolamine andpegylatedamine.
3. The compound as claimed in claim 1, wherein the representative compounds include;
i. 8-(dimethylamino)- 10-isopropylfluoranthene-7-carbonitrile;
ii. 10-Phenyl-8-(pyrrolidin-l-yl)fIuoranthene-7-carbonitrile;
iii. 10-(4-Methoxyphenyl)-8-(piperidin- 1 -yl)fluoranthene-7-carbonitrile;
iv. 8-(piperidin- 1 -yl)- 10-(thiophen-2-yl)fluoranthene-7-carbonitrile;
v. 10-(benzo[d][l ,3]dioxol-5-yl)-8-(piperidin-l-yl)fluoranthene-7-carbonitrile; vi. 8-(piperidin- 1 -yl)- 10-(3 ,4,5-trimethoxyphenyl)fluoranthene-7-carbonitrile; vii. 10-(4-nitrophenyl)-8-(piperidin- 1 -yl)fluoranthene-7-carbonitrile;
viii. 10-(4-hydroxyphenyl)-8-(piperidin- 1 -yl)fluoranthene-7-carbonitrile;
ix. 10-(3 ,4-dihydroxyphenyl)-8-(piperidin- 1 -yl)fluoranthene-7-carbonitrile;
x. 8-(piperidin- 1 -yl)- 10-(3,4,5-trihydrsoxyphenyl)fluoranthene-7-carbonitrile; xi. 10-(4-aminophenyl)-8-(piperidin- 1 -yl)fluoranthene-7-carbonitrile;
xii. 8-(bis(2-hydroxyethyl)amino)- 10-phenylfluoranthene-7-carbonitrile;
xiii. 8-((2-hydroxyethyl)(methyl)amino)-10-(4-methoxyphenyl)fluoranthene-7- carbonitrile;
xiv. 8-((2-hydroxyethyl)(methyl)amino)- 10-(4-methoxyphenyl)fluoranthene-7- carbonitrile;
xv. 8-((2;'bromoethyl)(methyl)amino)- 10-(4-methoxyphenyl)fluoranthene-7- carbonitrile.
A process for preparing donor-acceptor fluoranthene compounds of general formula I comprising the steps of ;
(i) reacting a compound having general formula S-1 with a compound having general formula S-2 in an organic solvent in the presence of a base at a temperature ranging between -78°C to 100°C for a period ranging between 1 minute to 24 hr to obtain a reaction mixture wherein,
R1, R2, ;R3, R4, R5, R6, R7, R8 are independently selected from the groups comprising hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl, unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or substituted acyloxy, unsubstituted or substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontiifluoride, nitro; wherein the word "substituted" means substitution 'with a group selected from halogen(s), nitrile(s), ester(s), hydroxy(s), alkoxy(s), mercapto(s), carbontrifluoride(s), nitro(s), amino group(s) or Ci - to C20-units;
wherein X is a donor group comprising unsubstituted or substituted amine, unsubstituted or substituted alkoxyl, unsubstituted or Substituted alkylthio group;
(ii) isolating and purifying the compound of general formula I from the reaction mixture.
The process as claimed in claim 4, wherein the organic solvent is selected from the group comprising DMF, THF, DMSO, DC and isopropanol.
The process as claimed in claim 4, wherein the base is selected from the group comprising KOH, NaOH, NaH, KH, K2C03 and Cs2C03.
Use of donor-acceptor fluoranthenes having the general formula I alone or in combination with other fluorescent compounds and derivatives thereof for fluorescence-based cell imaging;
I
wherein R1, R2, R3, R4, R5, R6, R7, R8 are independently selected from the groups comprising hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted aryl unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or substituted acyloxy, unsubstituted or substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro;wherein the word "substituted" means substitution with a group selected from halogen(s), nitrile(s), ester(s), hydroxy(s), alkoxy(s), mercapto(s), carbontrifluoride(s), nitro(s), amino group(s) or Ci- to C20-units; wherein X is a donor group comprisingunsubstituted or substituted amine, unsubstituted or substituted alkoxyl, unsubstituted or substituted alkylthio group; wherein CN is an acceptor group.
The use of a donor-acceptor fluoranthenes according to claim 7, wherein said fluorescence- based cell imaging or analysis is either a monocolor or a multi-color imaging or analysis.
A method for fluorescence-based imaging or analysis of cells and/or cellular components, comprising the following steps: i) staining cellular components with a donor-acceptor fluoranthenes having the general formula I, and derivatives thereof
wherein Rl , R2, R3, R4, R5, R6, R7, R8 are independently selected from the groups comprising of hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkoxyl, unsubstituted or substituted
) aryl unsubstituted or substituted cycloaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylthio, unsubstituted or substituted amino, unsubstituted or substituted acylamino, unsubstituted or substituted arylamino, unsubstituted or substituted acylthio, unsubstituted or substituted acyl, unsubstituted or substituted aroyl, unsubstituted or
> substituted acyloxy, unsubstituted or substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro; wherein the word "substituted" means substitution of the moiety with a group selected from one or more halogen(s), nitrile(s), ester(s), hydroxy(s), alkoxy(s), ) mercapto(s), carbontrifluoride(s), nitro(s), amino group(s) or CI - to C20-units; wherein X is a donor group comprising of unsubstituted or substituted amino, unsubstituted or substituted alkoxyl, unsubstituted or substituted alkylthio group; i wherein CN is an acceptor group; ii) exciting the fluoranthene dye of step i) with laser light in the wave length range from 405 nm to 665 nm;
iii) detecting the light emitted in step (ii);
I iv) optionally, generating images with the emission data obtained in step iii);
v) optionally performing an analysis with the data obtained in step iii) or the images obtained in step iv).
10. The method according to claim 9, wherein the cellular components stained with the fluoranthene dye of formula I in step i) are lipid droplets.
1 1. The method according to any one of claims 9-10, wherein 1 , 2 or 3 other excitable ) fluorescent dye(s) are used, resulting in 2-color, 3-color or 4-color imaging.
12. The method according to anyone of claims 9-1 1, wherein living or fixed cells are subjected to said fluorescence-based imaging or analysis of cells and/or cellular components.
> 13. The method according to any one of claims 9-12, wherein a confocal laser scanning microscope, a spinning disc microscope, a two-photon microscope, a conventional epifluorescence microscope, a structured illumination microscope, or a single plane illumination microscope is used.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN807/DEL/2013 | 2013-03-19 | ||
IN807DE2013 | 2013-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014147642A1 true WO2014147642A1 (en) | 2014-09-25 |
Family
ID=50732230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2014/000156 WO2014147642A1 (en) | 2013-03-19 | 2014-03-10 | Substituted fluoranthene-7-carbonitriles as fluorescent dyes for cell imaging applications |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014147642A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016138457A1 (en) * | 2015-02-26 | 2016-09-01 | Sony Corporation | Phenylethynylnaphthalene dyes and methods for their use |
US9689877B2 (en) | 2014-01-16 | 2017-06-27 | Sony Corporation | Water soluble fluorescent or colored dyes and methods for their use |
US9765220B2 (en) | 2013-08-22 | 2017-09-19 | Sony Corporation | Water soluble fluorescent or colored dyes and methods for their use |
US9851359B2 (en) | 2016-04-06 | 2017-12-26 | Sony Corporation Of America | Ultra bright dimeric or polymeric dyes with spacing linker groups |
US10865310B2 (en) | 2015-05-11 | 2020-12-15 | Sony Corporation Of America | Ultra bright dimeric or polymeric dyes |
US11142647B2 (en) | 2016-04-01 | 2021-10-12 | Sony Group Corporation | Ultra bright dimeric or polymeric dyes |
CN114262272A (en) * | 2021-12-24 | 2022-04-01 | 山东大学 | Naphthalene-indene diketone donor-acceptor compound, preparation method thereof and application thereof in lipid drop wash-free fluorescent probe |
US11312736B1 (en) | 2017-10-05 | 2022-04-26 | Sony Corporation | Programmable polymeric drugs |
US11352502B2 (en) | 2019-09-26 | 2022-06-07 | Sony Group Corporation | Polymeric tandem dyes with linker groups |
US11370922B2 (en) | 2016-05-10 | 2022-06-28 | Sony Corporation | Ultra bright polymeric dyes with peptide backbones |
US11377563B2 (en) | 2016-06-06 | 2022-07-05 | Sony Corporation | Ionic polymers comprising fluorescent or colored reporter groups |
US11390754B2 (en) | 2016-05-10 | 2022-07-19 | Sony Corporation | Compositions comprising a polymeric dye and a cyclodextrin and uses thereof |
US11434377B2 (en) | 2016-04-01 | 2022-09-06 | Sony Corporation | Ultra bright dimeric or polymeric dyes with rigid spacing groups |
US11453783B2 (en) | 2018-03-21 | 2022-09-27 | Sony Corporation | Polymeric tandem dyes with linker groups |
US11685835B2 (en) | 2016-05-11 | 2023-06-27 | Sony Corporation | Ultra bright dimeric or polymeric dyes |
US11827661B2 (en) | 2015-02-26 | 2023-11-28 | Sony Group Corporation | Water soluble fluorescent or colored dyes comprising conjugating groups |
US11874280B2 (en) | 2018-03-19 | 2024-01-16 | Sony Group Corporation | Use of divalent metals for enhancement of fluorescent signals |
US11931419B2 (en) | 2017-11-16 | 2024-03-19 | Sony Group Corporation | Programmable polymeric drugs |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011018184A1 (en) | 2009-08-12 | 2011-02-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. | Fluorescence-based imaging and analysis of cells and cellular components using lipophilic dyes with improved specificity, spectral properties and photostability |
WO2012118444A1 (en) | 2011-03-01 | 2012-09-07 | Agency For Science, Technology And Research | Novel compounds with photoluminescnce properties and applications thereof |
-
2014
- 2014-03-10 WO PCT/IN2014/000156 patent/WO2014147642A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011018184A1 (en) | 2009-08-12 | 2011-02-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. | Fluorescence-based imaging and analysis of cells and cellular components using lipophilic dyes with improved specificity, spectral properties and photostability |
WO2012118444A1 (en) | 2011-03-01 | 2012-09-07 | Agency For Science, Technology And Research | Novel compounds with photoluminescnce properties and applications thereof |
Non-Patent Citations (18)
Title |
---|
ATUL GOEL ET AL: "New Fluoranthene FLUN-550 as a Fluorescent Probe for Selective Staining and Quantification of Intracellular Lipid Droplets", ORGANIC LETTERS, vol. 16, no. 3, 10 January 2014 (2014-01-10), pages 756 - 759, XP055130632, ISSN: 1523-7060, DOI: 10.1021/ol403470d * |
ATUL GOEL ET AL: "Synthesis, Electrochemical and Optical Properties of Stable Yellow Fluorescent Fluoranthenes", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 75, no. 11, 6 May 2010 (2010-05-06), pages 3656 - 3662, XP055130639, ISSN: 0022-3263, DOI: 10.1021/jo100420x * |
CAMPO ET AL., J. AM. CHEM. SOC., vol. 125, 2003, pages 11506 |
FERNANDEZ-CHECA, J. C., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 304, 2003, pages 471 |
GREENSPAN ET AL., J. LIPID RES., vol. 26, 1985, pages 781 |
HAROLD W. MOORE ET AL: "Chemistry of azido quinones. Cyanophenols from 4-alkynyl-3-azido-1,2-benzoquinones", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 52, no. 12, 1 June 1987 (1987-06-01), pages 2530 - 2537, XP055130635, ISSN: 0022-3263, DOI: 10.1021/jo00388a034 * |
JANA ET AL., ORG. LETT., vol. 10, 2008, pages 4795 |
LISTENBERGER L L AND BROWN D A: "Fluorescent detection of lipid droplets and associated proteins", CURRENT PROTOCOLS IN CELL BIOLOGY, JOHN WILEY & SONS, INC, US, vol. supplement 35, 1 June 2007 (2007-06-01), pages 24.2.1 - 24.2.11, XP002547574, ISSN: 1934-2500, [retrieved on 20070601], DOI: 10.1002/0471143030.CB2402S35 * |
MARCINOW, J. ORG. CHEM., vol. 67, 2002, pages 3537 |
NAYAK, R. C.; SAHASRABUDDHE, A. A.; BAJPAI, V. K.; GUPTA, C. M., MOL. BIOCHEM. PARASITOL., vol. 143, 2005, pages 152 |
ONODERA ET AL., ORG. LETT., vol. 7, 2005, pages 4029 |
SPANDL ET AL., TRAFFIC, vol. 10, 2009, pages 1579 |
VIALA ET AL., J. ORG. CHEM., 2002, pages 4185 |
WALTHER ET AL., ANNU. REV. BIOCHEM., vol. 81, 2012, pages 687 - 714 |
WEGNER ET AL., J. ORG. CHEM., vol. 68, 2003, pages 883 |
WEHMEIER ET AL., CHEM. EUR. J., vol. 7, 2001, pages 2197 |
WU ET AL., J. AM. CHEM. SOC., vol. 128, 2006, pages 6870 |
YOSHIHARU NAKANO ET AL: "Fluorescence Properties of Polycyanoanilines Synthesized from Elektrophilic Ethylenes and Malononitrile Derivatives", JOURNAL OF PHOTOSCIENCE, 1 January 2000 (2000-01-01), pages 193 - 198, XP055130650, Retrieved from the Internet <URL:http://img.kisti.re.kr/soc_img/society//ksph/E1JPAU/1999/v6n4/E1JPAU_1999_v6n4_193.pdf#view=FitH&toolbar=1&statusbar=0&messages=0&scrollbar=1> [retrieved on 20140721] * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10954391B2 (en) | 2013-08-22 | 2021-03-23 | Sony Corporation | Water soluble fluorescent or colored dyes and methods for their use |
US9765220B2 (en) | 2013-08-22 | 2017-09-19 | Sony Corporation | Water soluble fluorescent or colored dyes and methods for their use |
US11434374B2 (en) | 2013-08-22 | 2022-09-06 | Sony Corporation | Water soluble fluorescent or colored dyes and methods for their use |
US11939474B2 (en) | 2013-08-22 | 2024-03-26 | Sony Group Corporation | Water soluble fluorescent or colored dyes and methods for their use |
US10435563B2 (en) | 2013-08-22 | 2019-10-08 | Sony Corporation | Water soluble fluorescent or colored dyes and methods for their use |
US9689877B2 (en) | 2014-01-16 | 2017-06-27 | Sony Corporation | Water soluble fluorescent or colored dyes and methods for their use |
US10036754B2 (en) | 2014-01-16 | 2018-07-31 | Sony Corporation | Water soluble fluorescent or colored dyes and methods for their use |
US11827661B2 (en) | 2015-02-26 | 2023-11-28 | Sony Group Corporation | Water soluble fluorescent or colored dyes comprising conjugating groups |
WO2016138457A1 (en) * | 2015-02-26 | 2016-09-01 | Sony Corporation | Phenylethynylnaphthalene dyes and methods for their use |
CN107406353A (en) * | 2015-02-26 | 2017-11-28 | 索尼公司 | Phenylene-ethynylene naphthalocyanine dye and the method for their purposes |
US11084932B2 (en) | 2015-02-26 | 2021-08-10 | Sony Group Corporation | Phenylethynylnaphthalene dyes and methods for their use |
US10865310B2 (en) | 2015-05-11 | 2020-12-15 | Sony Corporation Of America | Ultra bright dimeric or polymeric dyes |
US11142647B2 (en) | 2016-04-01 | 2021-10-12 | Sony Group Corporation | Ultra bright dimeric or polymeric dyes |
US11434377B2 (en) | 2016-04-01 | 2022-09-06 | Sony Corporation | Ultra bright dimeric or polymeric dyes with rigid spacing groups |
US10989715B2 (en) | 2016-04-06 | 2021-04-27 | Sony Corporation | Ultra bright dimeric or polymeric dyes with spacing linker groups |
US9851359B2 (en) | 2016-04-06 | 2017-12-26 | Sony Corporation Of America | Ultra bright dimeric or polymeric dyes with spacing linker groups |
US10866244B2 (en) | 2016-04-06 | 2020-12-15 | Sony Corporation Of America | Ultra bright dimeric or polymeric dyes with spacing linker groups |
US11370922B2 (en) | 2016-05-10 | 2022-06-28 | Sony Corporation | Ultra bright polymeric dyes with peptide backbones |
US11390754B2 (en) | 2016-05-10 | 2022-07-19 | Sony Corporation | Compositions comprising a polymeric dye and a cyclodextrin and uses thereof |
US11685835B2 (en) | 2016-05-11 | 2023-06-27 | Sony Corporation | Ultra bright dimeric or polymeric dyes |
US11377563B2 (en) | 2016-06-06 | 2022-07-05 | Sony Corporation | Ionic polymers comprising fluorescent or colored reporter groups |
US11312736B1 (en) | 2017-10-05 | 2022-04-26 | Sony Corporation | Programmable polymeric drugs |
US11931419B2 (en) | 2017-11-16 | 2024-03-19 | Sony Group Corporation | Programmable polymeric drugs |
US11874280B2 (en) | 2018-03-19 | 2024-01-16 | Sony Group Corporation | Use of divalent metals for enhancement of fluorescent signals |
US11453783B2 (en) | 2018-03-21 | 2022-09-27 | Sony Corporation | Polymeric tandem dyes with linker groups |
US11352502B2 (en) | 2019-09-26 | 2022-06-07 | Sony Group Corporation | Polymeric tandem dyes with linker groups |
US11945955B2 (en) | 2019-09-26 | 2024-04-02 | Sony Group Corporation | Polymeric tandem dyes with linker groups |
CN114262272B (en) * | 2021-12-24 | 2023-02-17 | 山东大学 | Naphthalene-indene diketone donor-acceptor compound, preparation method thereof and application thereof in lipid drop wash-free fluorescent probe |
CN114262272A (en) * | 2021-12-24 | 2022-04-01 | 山东大学 | Naphthalene-indene diketone donor-acceptor compound, preparation method thereof and application thereof in lipid drop wash-free fluorescent probe |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014147642A1 (en) | Substituted fluoranthene-7-carbonitriles as fluorescent dyes for cell imaging applications | |
US10495632B2 (en) | Azetidine-substituted fluorescent compounds | |
Wang et al. | A highly selective AIE fluorogen for lipid droplet imaging in live cells and green algae | |
WO2014106957A1 (en) | ASYMMETRICAL Si RHODAMINE AND RHODOL SYNTHESIS | |
CN105874319B (en) | Using the manufacturing method of positive charge AIE fluorogen specific detection and quantization cuorin and separate mitochondria and the AIE fluorogen | |
Zheng et al. | Biscarbazolylmethane-based cyanine: a two-photon excited fluorescent probe for DNA and selective cell imaging | |
CN112779001B (en) | Preparation and application of near-infrared viscosity fluorescent probe | |
WO2010028349A2 (en) | Fluorochromes for organelle tracing and multi-color imaging | |
US11591359B2 (en) | Enzyme-specific intracellularly-retained red fluorescent probe | |
Dakanali et al. | Self-calibrating viscosity probes: Design and subcellular localization | |
EP2778161B1 (en) | Two-photon fluorescent probe using naphthalene as matrix and preparation method and use thereof | |
Dai et al. | A two-photon mitotracker based on a naphthalimide fluorophore: Synthesis, photophysical properties and cell imaging | |
CN105693736A (en) | Glycine structure containing Rhodamine photo-control fluorescent switch probe and application thereof | |
Capodilupo et al. | A series of diphenylamine-fluorenone derivatives as potential fluorescent probes for neuroblastoma cell staining | |
de Jong et al. | Development and characterization of BODIPY-derived tracers for fluorescent labeling of the endoplasmic reticulum | |
Sung et al. | Gold (I)-Catalyzed Intramolecular Hydrothiophenylation of N-Thiophen-3-yl Alkynylamides for Accessing Thieno [3, 2-b] pyridine-5 (4 H)-ones: Development of F-Actin Specific Fluorescent Probes | |
EP2395055A1 (en) | Fluorescent solvatochromic pigment | |
CN108440386B (en) | Preparation method of two-photon fluorescence pH probe and application of two-photon fluorescence pH probe in cell imaging | |
WO2018133859A1 (en) | Compounds and methods for detection of hydrogen peroxide | |
EP3445348B1 (en) | Fluorescent compounds, production methods and uses thereof | |
EP3865544A1 (en) | Fluorescent rhodamine dyes with enhanced cell permeability | |
JP3624214B2 (en) | Fluorescent probe for magnesium ion measurement | |
JP5510914B2 (en) | New cell-permeable fluorescent dye | |
KR102282950B1 (en) | Novel fluorescent substance based on oxazepine and use thereof | |
US20230052551A1 (en) | Fluorescent probe for detection of enpp activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14724516 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14724516 Country of ref document: EP Kind code of ref document: A1 |